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1 Summary 
Transplantation of organs and cells saves and prolongs thousands of lives every year. 
Surgical techniques were significantly improved but major problems remain, in particular the 
host’s immune system. Despite advances in immunosuppressive therapies, chronic allograft 
rejection still occurs which is characterized by intimal thickening in the arteries and the 
replacement of graft parenchyma, a phenomenon called chronic transplant vasculopathy 
(CTV). Within three years after transplantation 45% of transplant patients are affected by 
CTV which leads to the failure of allografts of about 5% each year post transplantation. The 
reasons for its development and the mechanistic basis inducing CTV are still not clearly 
understood.  
In graft versus host disease (GVHD) and vascular rejection of solid organ transplants, 
vascular endothelial cells (EC) have been recognized as important targets for alloreactive 
cytotoxic T-lymphocytes (CTL) and the presence of CTL has been associated with CTV. 
Therefore, T-cell-mediated immunity and subsequent inflammation appear to be important 
features of the initiation and progression of CTV. The contribution of EC to CD8
+
  
T-cell activation and therefore their role in the development of chronic vascular rejection is 
still controversially discussed. 
For that reason and the fact that after transplantation of vascularised organs EC are the first 
graft cells encountered by host lymphocytes, the detailed interaction of vascular EC with 
CD8
+
 T-cells has been assessed in vivo in the first part of our study, in order to find out 
whether EC are able to activate or tolerize naive CD8
+
 T-cells. Using a transgenic mouse 
model with beta-galactosidase (β-gal) expression confined to the vascular endothelium  
(Tie2-LacZ mice) and the help of β-gal TCR transgenic CD8+ T-cells (Bg1 mice), the 
capacity of EC presenting a minor histocompatibility antigen (mhAg) to induce a CD8
+
 T-cell 
response was studied. We could show that mhAg presentation on EC was ignored by CD8
+
  
T-cells and was neither sufficient to activate nor to tolerize CD8
+
 T-cells. Moreover, the 
mhAg was cross-presented by BM-derived CD11c
+
 DC and led to spontaneous activation of 
β-gal-specific CD8+ T-cells in Tie2-LacZ mice. This identifies the priming of mhAg-specific 
CD8
+
 T-cells via DC as the critical step in the generation of alloimmune responses. 
Furthermore, no β-gal-specific CD8+ T-cell activation was induced after transplantation of 
fully vascularised heart or liver grafts from Tie2-LacZ mice into non-transgenic recipients 
confirming that CD8
+
 T-cell responses against mhAg cannot be initiated by EC. 
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In the second part of the study the major aim was to develop an experimental system that 
facilitates in vivo studies on the interaction of EC with activated CTL in a heart 
transplantation model. To this end, Tie2-LacZ hearts were heterotopically transplanted into 
C57BL/6 recipients. Tie2-LacZ hearts were accepted and showed no vascular inflammatory 
changes or neointima formation until day 100 post transplantation. Repetitive priming with  
β-gal peptide loaded DC induced a long-term β-gal-specific CTL response resulting in the 
induction of vascular inflammatory disease with neointima formation and vascular occlusion. 
Infection with β-gal recombinant mouse cytomegalovirus (MCMV-LacZ) however, led to a 
shorter activation of β-gal-specific CTL and thus to a less significant vascular inflammation in 
Tie2-LacZ hearts. Taken together, we suggest that it is the prolonged presentation of mhAg 
within secondary lymphoid organs that is responsible for the activation of EC-specific CTL 
and that activated CTL recognize thereafter mhAg specifically expressed on EC, leading to 
the development of chronic vascular rejection. 
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2 Zusammenfassung 
Durch die Transplantation von Organen oder Zellen werden jedes Jahr Menschenleben 
gerettet. Trotz medikamentösen Fortschritten zur Unterdrückung des Immunsystems 
entwickeln im Falle einer Knochenmarkstransplantation 60-70% der behandelten Patienten 
eine chronische Immunreaktion gegen das eigene Gewebe. Auch bei Organtransplantationen 
ist der Langzeiterfolg nicht garantiert und es kommt häufig zu spätem Organversagen. 
Chronische Abstossungsreaktionen, welche sich über Monate oder Jahre entwickeln, stellen 
den Hauptgrund für die Abstossung transplantierter Organe dar. Während der chronischen 
Abstossungsreaktion kommt es zur Verdickung der Intima der Arterien und zum Austausch 
von Transplantatparenchym, ein Prozess, der auch chronische Transplantatvaskulopathie 
genannt wird. Innerhalb der ersten drei Jahre nach der Transplantation entwickeln 45% der 
Transplantationspatienten solche vaskuläre Veränderungen, welche meist zum Organversagen 
führen. Diese Abstossungsreaktionen kommen in einer Häufigkeit von ungefähr 5% pro Jahr 
nach der Transplantation vor. Die Ursachen und die mechanistischen Grundlagen dafür sind 
nicht vollständig verstanden. 
Es wurde jedoch gezeigt, dass bei der Abstossungsreaktion vaskuläre Endothelzellen (EC) 
wichtige Zielzellen zytotoxischer T Zellen sind. Weiter konnte eine Korrelation zwischen 
dem Vorhandensein zytotoxischer T Zellen und dem Erscheinen chronischer Transplantat 
Vaskulopathie gezeigt werden. Die T Zellen-induzierte Immunität und die sich daraus 
entwickelnde Entzündung scheinen wichtige Faktoren für die Entstehung und Entwicklung 
vaskulärer Veränderungen zu sein. Welche Rolle EC im Bezug auf die CD8
+
 T Zellen-
Reaktivität und somit in der Entwicklung chronischer Abstossungsreaktionen haben, wird 
kontrovers diskutiert.  
Aus diesen Gründen und weil EC die ersten Zellen des transplantierten Organs sind, 
welche von Empfänger T Lymphozyten getroffen und erkannt werden, wurde im ersten Teil 
dieser Arbeit die Interaktion vaskulärer EC mit naiven CD8
+
 T Zellen am Tiermodell 
untersucht. In dieser Studie wurden transgene Mäuse verwendet, bei welchen die 
Exprimierung des Modelantigens Beta-galactosidase (β-gal) auf die vaskulären EC beschränkt 
ist (Tie2-LacZ Maus). Zusätzlich standen T Zell Rezeptor transgene β-gal-spezifische CD8+ 
Zellen zur Verfügung. Es wurde untersucht, ob EC, die ein nominales Antigen präsentieren, 
eine CD8
+ 
T Zell-Antwort generieren können. Es konnte gezeigt werden, dass nominales 
Antigen von CD8
+
 T Zellen ignoriert wurde und weder zu einer Aktivierung, noch zu einer 
Toleriserung führte. Weiter wurde gezeigt, dass die Kreuz-Präsentation des Antigens durch 
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CD11c
+
 dendritische Zellen (DC) zur spezifischen Aktivierung und Proliferierung der CD8
+
  
T Zellen führte. Diese Tatsache lässt das Priming der Antigen-spezifischen CD8
+
 T Zellen 
durch DC als einen kritischen Schritt bei der Generierung einer Immunantwort erkennen. 
Außerdem wurde auch im Transplantationsmodel, bei welchem Tie2-LacZ Herzen oder 
Lebern in Wildtyp-Mäuse transplantiert wurden, keine CD8
+
 T Zell-Aktivierung beobachtet. 
Dies bestätigt, dass EC nicht fähig sind, eine CD8
+
 T Zell-Antwort gegen ein nominales 
Antigen zu induzieren.  
Im zweiten Teil unserer Studie war das Hauptziel, ein experimentelles System, welches die 
Untersuchungen der Interaktion von EC mit aktivierten zytotoxischen T Zellen im 
Transplantationsmodel des Herzens erleichtert, zu entwickeln. Dazu wurden Tie2-LacZ 
Herzen heterotop in C57BL/6 Mäuse transplantiert. Diese Herzen wurden von den Wildtyp-
Mäusen akzeptiert und bis 100 Tage nach der Transplantation konnten keine 
antigenspezifischen Gefässveränderungen beobachtet werden. Durch die Aktivierung von  
β-gal-spezifischen CD8+ zytotoxischen T Zellen mittels Injektion β-gal-Peptid beladener DC 
kam es zu vaskulären Entzündungen und der Bildung von Neointima mit kompletter 
Gefässokklusion. Diese entzündlichen Veränderungen waren nach der Infektion der Mäuse 
mit dem β-gal-rekombinanten Maus-Cytomegalievirus weitaus weniger ausgeprägt. 
Zusammengefasst kann gesagt werden, dass die verlängerte Präsentation von Antigen in 
sekundären lymphatischen Organen für die Aktivierung von EC-spezifischen zytotoxischen  
T Zellen verantwortlich ist. Aktivierte zytotoxische T Zellen erkennen daraufhin das Antigen, 
welches durch EC exprimiert und präsentiert wird, und tragen so zur Entstehung einer 
chronischen Abstossungsreaktion bei. 
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3 Introduction 
In a first part of this work, the general principles of immune activation, in particular, T-cell 
reactivity, were summarized. Furthermore, problems of organ and cell transplantation, as well 
as the role of vascular EC and CD8
+
 T-cells in allotransplantation, were described in order to 
be acquainted with the present knowledge concerning the interaction of vascular EC with 
CD8
+
 T-cells. 
3.1 General principles of immune activation 
The main role of the immune system is to protect the individual from infections. To fulfil 
this goal, two major components of the immune system, the innate and the adaptive immunity, 
work together. Innate immunity is considered as the less specific part and provides the first 
line of defence against infectious agents. It comprises molecular and cellular mechanisms that 
are not pathogen-specific but are present before onset of the infection. On the other hand the 
adaptive immune system, regarded as the specific part, only comes into play when there is 
antigenic challenge to the organism. A specific response can be observed within five or six 
days after the initial contact with the antigen and is characterized by its high specificity for the 
antigen and the ability to provide immunologic memory. Furthermore, the recognition of 
billions of single structures is possible through the capability of the adaptive immune system 
to generate a remarkable diversity in recognition molecules. Moreover, it has the capacity to 
discriminate self from non-self (Billingham et al., 1953; Burnet and Fenner, 1949; Burnet, 
1957). 
The major mediators of the adaptive immune system are B- and T-lymphocytes.  
B-lymphocytes produce specific antibodies upon activation, which primarily bind 
extracellular agents and neutralize the pathogen directly. CD4
+
 T-lymphocytes provide either 
direct help to B cells, involving CD40L:CD40 interaction and the production of cytokines, or 
they facilitate CD8
+
 T-cell expansion and activate macrophages by the production of 
cytokines, such as IL-2, IFNγ and TNF. CD8+ T-cells are the cytotoxic T-cells which have the 
ability to directly kill the infected cells via cell-cell interaction. By the secretion of IFNγ and 
other cytokines they exert further effector function. The main targets of T-cells are peptides 
derived from infectious agents or intracellular antigens bound to major histocompatibility 
complexes (MHC). Peptide antigens have to be processed, which implies the digestion of the 
protein into peptides and presentation on MHC molecules by antigen presenting cells (APC), 
since the T-cell receptor (TCR) recognizes foreign only in the combination with self. There 
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are two types of MHC molecules: MHC class I molecules, expressed on almost all nucleated 
cells and recognized by CD8
+
 T-cells and the MHC class II molecules, expressed on 
professional APC such as dendritic cells (DC), macrophages and B-lymphocytes. MHC II 
molecules are recognized by CD4
+
 T-cells.  
3.1.1 Antigen-presenting cells 
Strictly speaking, all nucleated cells could be assigned as APC since they all express  
MHC I or MHC II molecules. But according to convention, cells presenting peptide on MHC 
class I molecules to CD8
+
 T-cells are referred to as target cells. Only cells that display peptide 
via class II molecules are called professional APC. Professional APC are hematopoietic cells 
whereby three types of cells belonging to APC exist: DC, macrophages and B-lymphocytes. 
DC, a minor cell population in lymphoid tissues, are considered the prototypic professional 
APC (Banchereau et al., 2000; Guermonprez et al., 2002; Ludewig et al., 1998a; Steinman 
and Cohn, 1973; Steinman, 1991). They are the most significant and potent APC, able of 
inducing T-cell responses following infection or organ transplantation. DC constitutively 
express high levels of both class I and II MHC molecules and members of the co-stimulatory 
B7 family. Therefore, they are more potent in antigen presentation than  
B-lymphocytes and macrophages, which both have to be activated prior to acquiring the 
ability of antigen presentation. Furthermore, DC have the unique capacity to migrate to the 
periphery, the site of inflammation where they act as sentinels for pathogen-derived structures 
(Pulendran et al., 2001). As soon as they sense such structures through their pattern 
recognition receptors, such as Toll-like receptors, they undergo a maturation process 
including up-regulation of costimulatory molecules (Banchereau and Steinman, 1998). The 
exposure to proinflammatory cytokines and the ligation of the costimulatory molecule CD40 
also lead to their activation (Bennett et al., 1998). During maturation, DC capture antigen, 
internalize it, either by phagocytosis or by endocytosis and thereafter modify their homing 
receptors (Roake et al., 1995). After having fully matured, they transport antigen from the 
periphery to local lymphoid tissue and present the processed antigen on their membrane 
bound to MHC molecules to CD4
+ 
and CD8
+
 T-cells. Specific T-cells recognize this complex 
and interact with the DC. Thereafter DC produce costimulatory signals, inducing complete 
activation of the T-cells. There is accumulating evidence that DC play a key role in T-cell 
immunity. For example, in a mouse model, CD11c
+
 DC depletion was accompanied by a 
complete absence of primed CTL after infection with Listeria monocytogenes or with 
Introduction 
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Plasmodium yoelli (Jung et al., 2002), confirming that DC have the ability to prime naive  
T-lymphocytes during inflammation or infection. 
However, non-hematopoietic cells, i.e., vascular EC, have also been shown to act as APC. 
EC express MHC class I molecules and can induce the expression of MHC class II molecules 
upon inflammation via proinflammatory cytokine such as IFNγ (Marelli-Berg et al., 2000; 
Pober et al., 1997) and thereby display antigen to CD8
+
 and CD4
+
 T-lymphocytes. The 
antigen presenting function of EC works only for short periods of time during a sustained 
inflammatory response, therefore EC are called “semiprofessional” APC. EC present antigen 
to T-cells via the direct pathway, in the context of allograft transplantation where they display 
allo-MHC-peptide complexes, or via the indirect pathway which involves cross-presentation 
of antigens (Pober et al., 1997; Epperson and Pober, 1994; Rose, 1998; Bagai et al., 2005a; 
Limmer et al., 2000; Limmer et al., 2005; Valujskikh et al., 2002a). Although EC have the 
capacity to stimulate allogeneic CD8
+
 T-cells and memory allogeneic CD4
+
 T-cells, can they 
neither activate naive alloreactive CD4
+
 T-cells in vitro and in vivo nor are they able to 
activate resting T-cells specific for a minor histocompatibility antigen (mhAg) in vitro (Bagai 
et al., 2005a; Kreisel et al., 2002b; Kreisel et al., 2004; Marelli-Berg et al., 2000; Marelli-Berg 
et al., 2001). There is even evidence for EC to induce T-cell tolerance (Berg et al., 2006; 
Limmer et al., 2000; Limmer et al., 2005; Marelli-Berg et al., 2000). However, their 
capability of being a semiprofessional APC, regardless whether they induce T-cell activation 
or tolerization, is of main importance in the context of solid organ and bone marrow (BM) 
transplantation.  
Nonetheless, not only EC have been shown to induce T-cell tolerance, but DC too. While 
they activate T-cells during inflammation and infection, they are immature under steady state 
conditions and induce peripheral T-cell tolerance, see Figure 1 (Abbas and Sharpe, 2005) 
(Probst et al., 2005; Probst et al., 2003; Steinman et al., 2003b; Steinman et al., 2003a; 
Steinman, 2003). 
3.1.2 T-cell activation 
Naive T-lymphocytes circulate via blood through secondary lymphoid organs and home 
with the help of CD62L and CCR7 expression (Sallusto et al., 1999). Without previous 
activating stimulus they are not able to enter peripheral non lymphoid tissue. They need 
antigen presentation by professional APC within the secondary lymphoid organs, referred to 
as signal 1, and thereafter suitable costimulation, referred to as signal 2, to be activated and to 
differentiate into full effector T-cells (Lakkis et al., 2000; Salomon and Bluestone, 2001). 
These interactions are based on cell-cell contact which demands the special microenvironment 
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of organized lymphoid tissue that provides the necessary inflammatory milieu with antigen 
location, cytokines and interleukins, and enhances the chance of specific antigen encounters 
(Zinkernagel et al., 1997). After interaction of the TCR with the APC, CD28 and CD40L 
expression on T-cells is up-regulated and costimulation by engagement of one or more T-cell 
surface receptors with their specific ligands (CD40, CD80, CD86) on APC is provided. 
Differentiated T-cells are preferentially recruited to sites of inflammation. Via the expression 
of adhesion molecule ligands (L-selectin, LFA-1, VLA-4, Mac-1) they make contact to 
adhesion molecules, such as P-selectin, E-selectin, VCAM-1 and ICAM-1 on the activated 
endothelium and enter the periphery, to fulfil their task to protect the individual from 
infections (Campbell et al., 1998; Rao et al., 2007).  
3.1.3 T-cell tolerance 
T-cell development is a highly coordinated process with the main goal of reaching a 
maximal degree of diversity and of removing all T-lymphocytes that recognize self-antigen to 
prevent autoimmune diseases. A major mechanism in accomplishing self-tolerance is the 
elimination of potentially self-reactive T-lymphocytes during their development in the 
thymus. This negative selection of T-cells, referred to as central tolerance, has been shown to 
play a key role (Kappler et al., 1987).  
3.1.3.1 Central tolerance 
T-cell progenitors migrate from the BM to the thymus, where they undergo maturation. 
Maturation includes rearrangements of the germ-line TCR genes and the expression of 
various membrane markers. Developing T-cells in the thymus, the so called thymocytes, 
proliferate and differentiate along determined pathways to become functionally distinct 
subpopulations of mature T-cells. During this process they are submitted to positive and 
negative selection. Whereas positive selection permits the survival of T-cells with a TCR able 
of recognizing self-MHC molecules, negative selection eliminates T-cells with too high 
affinity towards self-MHC plus self-antigens. These self-antigens consist of those that are 
ubiquitous expressed, and those who are restricted to a few tissues, referred to as tissue-
specific antigens (TSAs). TSAs are expressed on medullary thymic epithelial cells (mTECs) 
(Kyewski and Derbinski, 2004) and BM-derived DC which capture the TSAs from mTECs 
(Gallegos and Bevan, 2004; Speiser et al., 1989) and present it to the thymocytes. 
However, central tolerance seems to be incomplete and potentially self-reactive T-cells 
escape negative selection and are released into the periphery where they could become 
Introduction 
- 14 - 
 
activated by professional APC, presenting self-antigens, and thereafter induce autoimmunity. 
In particular, T-cells with low avidity for self-antigen can escape central tolerance (Zehn and 
Bevan, 2006) and it is possible that other self-proteins, for which tolerance is required, may 
not access the thymus. Therefore, it is not surprising that further mechanisms in the periphery 
control self reactivity.  
3.1.3.2 Peripheral tolerance 
The induction of peripheral tolerance is an imperative physiological process necessary to 
supplement central tolerance (Kurts et al., 1997; Probst et al., 2003). Particularly at sites of 
infection, where maturing DC process and present self- and non-self-antigens at the same 
time, efficient tolerance mechanisms are of main importance.  
One major mechanism of peripheral tolerance is the induction of T-cell tolerance via 
steady-state DC. DC that have not been activated through inflammation or infection have an 
immature phenotype. Although they efficiently capture antigen, they lack high expression of 
co-stimulatory molecules and do not express CCR7. Despite the fact that they deliver signal 1 
under steady state conditions, they lack the ability to deliver signal 2, resulting in T-cell 
tolerance. (Banchereau and Steinman, 1998). This has been shown to be mediated through 
PD-1 and CTLA-4 (Probst et al., 2005; Sakaguchi et al., 2006b). Upon recognition of self-
antigens presented by DC, T-cells undergo proliferation but are ultimately deleted from the 
peripheral T-cell repertoire.  
Moreover, DC have also been shown to induce tolerance by the activation of 
CD4
+
CD25
+
Foxp3
+
 regulatory T-cells (Sakaguchi, 2004). CD4
+
CD25
+
Foxp3
+ 
regulatory T-
cells (Tregs) are known to be essential in many processes of the immune system. They play a 
crucial role in the maintenance of maternal tolerance to the foetus (Aluvihare et al., 2004), in 
the prevention of autoimmunity (Sakaguchi et al., 2006a) and in the inhibition of antitumor 
immunity (Beyer and Schultze, 2006). Furthermore, they are important in the regulation of 
immunity to viral and parasite infections (Belkaid et al., 2006; Rouse et al., 2006). Tregs 
develop in the thymus where they get positively selected (Bensinger et al., 2001). It has been 
shown that the Treg repertoire is enriched in auto specific cells (Fisson et al., 2003; Hsieh et 
al., 2004). This is consistent with what can be found looking at their central function in 
controlling autoreactive T-lymphocytes. However, Tregs become specifically activated by the 
presentation of autoantigens through DC in secondary lymphoid organs (Fisson et al., 2003; 
Samy et al., 2005) and need IL-2 for their proliferation. In part, the effector mechanisms used 
by Tregs are mediated by CTLA4, expressed by Tregs, and its ligation with CD80 and CD86 
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on T-lymphocytes. Additionally, the suppression requires responsiveness of effector T-cells to 
TGF-β and the secretion of IL-10 by Tregs (Asseman et al., 1999; Fahlen et al., 2005). 
Furthermore, there is accumulating evidence for the tolerogenic capacity of EC. Liver 
sinusoidal EC (LSEC) have been shown to induce CD8
+
 T-cell tolerance to soluble, oral and 
tumour-derived antigens (Berg et al., 2006; Limmer et al., 2000; Limmer et al., 2005) and 
isolated murine lung EC negatively regulated CD8
+
 T-cell function (Marelli-Berg et al., 
2000).  
However, there is a third way of peripheral tolerance, which is immunologic ignorance 
where peripheral antigen is not visible to T-lymphocytes. Whether CD8
+
 T cell ignore a 
peripheral antigen or become tolerized has been shown to be a matter of antigen dose. When 
the tissue-specific antigen was expressed at low concentration, no cross-presentation by DC 
could be observed and indeed, there was no CD8
+
 T-cell response indicating that the CD8
+
  
T-cell compartment remained ignorant. In mice expressing antigen at higher doses the antigen 
was cross-presented and led to the peripheral deletion of specific CD8
+
 T-cells (Kurts et al., 
1999). It has further been demonstrated that CD8
+
 T-cells need the presence of the antigen in 
order to become tolerized, indicating that they are rather anergized than fully deleted (Lees et 
al., 2006). 
Nevertheless, it has been shown that peripheral tolerance mechanisms cannot entirely 
recompense for inefficiencies in central tolerance since deficiency of AIRE, the autoimmune 
regulator that controls the gene expression of peripheral antigens in TEC leading to central 
tolerance, resulted in autoimmune syndrome (Anderson, 2002; Villasenor et al., 2005). 
However, it is obvious that negative selection is not sufficient either to eliminate all 
potentially autoreactive T cells since the absence of the development and action of regulatory 
T-cells leads to the development of autoimmunity (Piccirillo and Shevach, 2004). 
Taken together, both central and peripheral tolerance mechanisms play a major role in 
inducing specific self-tolerance. Nevertheless, only peripheral mechanisms are involved in the 
induction of tolerance towards foreign antigens, such as allo-antigens in the case of 
transplantation where the induction of specific allogeneic tolerance is a major goal to prevent 
transplant rejection because it is not accompanied by a general immunosuppression of the 
patient. 
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Figure 1: Immune activation and tolerance induction by DC. Top, DC are activated by TLRs and other signals. 
They display antigens and express costimulatory molecules, which stimulate T-lymphocytes. Bottom, resting, 
immature DC induce T-lymphocytes tolerance since DC do not express sufficient amounts of costimulatory 
molecules or they engage inhibitory receptors on the T cells (from (Abbas and Sharpe, 2005)). 
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3.2 Transplantation 
Each year, transplantation of organs and cells between individuals saves or prolongs 
thousands of lives. Allogeneic BM transplantation for example, displays an extremely 
effective treatment of malignant blood cell disorders. However, despite improved 
immunosuppressive therapies, up to 60-70% of patients develop chronic GVHD. And despite 
advances in surgical techniques for organ transplantations and the better immunosuppressive 
drugs for acute rejection, successful long-term outcome of transplanted organs is still 
hampered by late graft failure since the major problem, the immune system, remains. 
However, transplantations are performed between members of the same species and thus 
referred to as allotransplants. The immune response to allotransplants is called alloreactivity. 
It is directed against allelic differences in MHC molecules between host and donor and leads 
to rejection of the transplanted organ. The immune system uses the same mechanisms evolved 
to protect the organism from foreign agents to cause rejection from genetically not identical 
donor grafts. Thus, alloreactivity includes T- and B-cell-mediated responses as well as innate 
immune responses. Clinically, it manifests as transplant rejection (host-versus-donor) or as 
GVHD. MHC graft rejection generally depends on both class I and class II antigens together 
and a rejected vascularised solid organ graft is characterized by its dense infiltrates of host 
lymphocytes. As a consequence, graft cell necrosis and graft vessel thrombosis are induced 
and lead to acute rejection, taking place one to two weeks after transplantation. For that 
reason, the success of all kind of transplants strongly depends at the beginning on the ability 
to prevent acute rejection by the use of immunosuppressive agents. However, despite 
advances in immunosuppressive therapies, chronic allograft rejection or chronic GVHD, 
which develop over months and years, still occur and display in the end the main limitations 
of long-term survival (Cecka, 1999; Keck et al., 1999).  
3.2.1 Alloreactivity  
T-lymphocytes mature in the thymus where they undergo positive and negative selection to 
subsequently recognize self-MHC molecules in combination with non-self peptides. There is 
no process that selects for, or against, the ability of the TCR to bind to MHC alleles that are 
not expressed by an individual. However, in the first scenario the TCR makes contact with 
both the peptide and the self MHC molecule as a complex, and foreign is only recognized in 
combination with self-MHC (MHC-restriction). On the contrary, the direct interaction of 
alloreactive T-lymphocytes with the non-self MHC molecule or the foreign peptide or even 
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with both is not MHC-restricted. Furthermore, direct recognition of the foreign MHC 
molecules by allogeneic T-cells is defined as the recognition of a major histocompatibility 
antigen, whereas minor histocompatibility antigens, in the context of allotransplantation, are 
defined as immunogenic peptides, which derive from cellular proteins from the graft 
(allorejection) or the host (GVHD), presented on MHC-I molecules and recognized by 
alloreactive T-cells. Naturally, alloresponses arise in the context of major and minor 
histocompatibility mismatches between donor and recipient. 
However, alloreactive T-lymphocytes have the ability to recognize peptide-MHC 
complexes that were not encountered during thymic development. This is characterized by 
lower specificity and binding affinities which goes along with a high precursor frequency that 
is 100 to 1000 times higher than the precursor frequency of T-cells specific for any single 
foreign-peptide-self-MHC complex (Lindahl and Wilson, 1977; Suchin et al., 2001). This 
explains the strong primary immune response where the high frequency of alloreactive T-cells 
(1 in 10
3
-10
4
) enables their detection. Nonetheless, a comprehensive model of how the 
peptide-allogeneic-MHC complex contributes to TCR alloreactivity is elusive. Some models 
suggest that T-cell activation derives entirely from interaction between the TCR and the 
allogeneic MHC molecules (Bevan, 1984), whereas other models explain the activation by a 
central role of the peptide (Matzinger and Bevan, 1977). According to these models, 
allorecognition and conventional recognition are two different mechanisms (Figure 2B). 
Despite the tendency to distinguish them, many recent findings reveal their similarities. 
Structural analyses have displayed that, although individual interactions differ, the type of 
TCR interactions with self and allogeneic MHC molecules are comparable (Figure 2A) and 
numerous studies have clearly shown the existence of alloreactive T-lymphocytes highly 
peptide specific (Alexander-Miller et al., 1993; Felix et al., 2007; Heath and Sherman, 1991; 
Heath et al., 1991; Mazza et al., 2007; Mendiratta et al., 1999; Tallquist et al., 1996; Weber et 
al., 1995; Whitelegg et al., 2005). Moreover, the ability of alloreactive TCR to identify 
multiple distinct peptide-allogeneic-MHC complexes, but each with a high degree of 
specificity, has been shown in several studies (Guimezanes et al., 2001; Mazza et al., 2007; 
Reiser et al., 2003; Tallquist et al., 1996). 
  Introduction  
 
- 19 - 
 
 
Figure 2: T-cell recognition of conventional and allogeneic complexes. (a) TCRs recognize both conventional 
peptide-self-MHC complexes and peptide-allogeneic-MHC complexes although these TCRs have never 
encountered the allogeneic-MHC molecules during thymic development. (b) In conventional recognition, the 
TCR makes contact with both the peptide and the self MHC molecule. In allorecognition some models suggest 
that the TCR primarily contacts the MHC molecule or the peptide. However, many alloreactive T-cells seem to 
interact with the peptide-allogeneic-MHC complex in a manner identical to conventional recognition (from 
(Felix and Allen, 2007)). 
3.2.1.1 Molecular basis of alloreactivity 
Within a species and even within individuals, MHC molecules show a huge degree of 
diversity. They are highly polymorphic. Hundreds of different MHC alleles are present in the 
human population. These alleles differ in their DNA sequences from one individual to another 
by 5 to 10%. The location of so many polymorphic amino acids within the binding site for 
processed antigen strongly suggest that allelic differences contribute to the observed 
differences in the ability of MHC molecules to interact with a given antigenic peptide. 
Polymorphism in the MHC α-helical residues can directly influence allorecognition, whereas 
polymorphism in the peptide-binding groove affects which peptides binds, as well as the 
overall conformation of the peptide-allogeneic-MHC complex (Bluestone et al., 1992; 
Chattopadhyay et al., 1994). Each peptide-MHC complex may take up a unique conformation, 
even when the same peptide is presented by both self and allogeneic MHC molecules. 
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Consequently, the surface that is recognized by the TCR is intimately linked to both the 
bound peptide and the MHC molecule. 
3.2.2 Graft versus host disease (GVHD) 
GVHD is the most severe and common immunological complication of BM transplantation 
(Horowitz et al., 1990). It occurs when donor T-cells recognize alloantigens on the host cells 
and mediate an immune response directed against the recipient. Usually, the recipient of the 
BM transplant is immunologically suppressed before BM grafting is performed. The 
activation and proliferation of alloreactive T-cells and the following cytokine generation 
induces inflammatory reactions in the skin, gastrointestinal tract, and liver. In patients with 
acute and chronic GVHD vascular injury in the skin has been observed (Biedermann et al., 
2002), indicating that EC are target cells of allospecific CTL. In severe cases these processes 
can lead to generalized erythroderma of the skin, gastrointestinal haemorrhage, and liver 
failure. Immunosuppressive drugs are used in order to inhibit the immune response of the 
donor. GVHD affects 50-70% of BM-transplant patients and is even induced in HLA-
identical BM transplantation where disparities in mhAg between the donor and the host lead 
to the induction of GVHD (Goulmy et al., 1983). 
3.2.3 Allograft rejection  
Most allograft rejections involve T-cell mediated responses; whereby acute and chronic 
allograft rejection can be distinguished.  
3.2.3.1 T-cell activation in acute and chronic rejection 
Due to improved immunosuppression regimen, acute rejection occurs with decreasing 
incidence after the first three months. Indeed, a high percentage of transplant recipients never 
experience episodes of acute rejection. However, in allotransplantation APC, responsible for 
T-cell activation, may potentially originate from either the donor graft (direct) or from the 
recipient (indirect, semi-direct). Donor APC are tissue-specific and only the determinants 
expressed on donor APC will also be expressed by parenchymal cells of the graft. After 
transplantation of vascularised solid organs, donor APC travel to the secondary lymphoid 
organs of the host where they directly activate naive CD4
+
 and CD8
+
 T-lymphocytes leading 
to the induction of acute allograft rejection (Hernandez-Fuentes et al., 1999). In the case of 
vascularised grafts, memory alloreactive T-cells could be directly activated by donor APC in 
the periphery, e.g., EC, without need of co-stimulation and the environment of secondary 
lymphoid structures (Perez et al., 1998; Pober et al., 1996; Epperson and Pober, 1994). 
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Nonetheless, over the time, donor APC are replaced by recipient APC and the indirect 
pathway becomes more important. This pathway is characterized by the presentation of donor 
antigens on recipient APC. Host APC enter the graft, pick up donor antigen, particularly 
allogeneic MHC antigens, and present it on self MHC-I (cross-presentation) and MHC-II 
molecules to naive T-lymphocytes in secondary lymphoid organs. The indirect pathway plays 
a major role during chronic rejection (Hornick et al., 2000; Shirwin, 1995). Furthermore, 
cross-presentation of alloantigen by DC is a phenomenon not restricted exclusively to DC. In 
the context of allotransplantation EC have also been shown to cross-present antigen (Bagai et 
al., 2005a). Recently, a third approach for presentation of foreign MHC molecules has been 
described, the so called semi-direct pathway. In the semi-direct pathway recipient DC are able 
to acquire intact functional MHC molecules from graft cells and thereafter induce antigen 
specific T-cell responses (Herrera et al., 2004). However, no matter which way of activation 
is used, naive cells can only be primed within the microenvironment of the secondary 
lymphoid organs and are not able to reject an allograft in the absence of those (Lakkis et al., 
2000). 
Nevertheless, although acute rejection can be prevented by immunosuppressive therapy, 
chronic rejection developing over months and years and characterized by the replacement of 
graft parenchyma still develops. It leads to the failure of allografts of about 5% each year 
posttransplantation and frequently necessitates retransplantation (Cecka, 1999; Keck et al., 
1999). It is important to point out that this rate has not been altered by the introduction of new 
immunosuppressive drugs compared to the tremendous reduction in the rate of acute allograft 
rejection.  
3.2.3.2 Chronic rejection 
There are two different forms of chronic rejections. The first is defined as chronic 
parenchymal cell rejection where graft failure is due to progressive immune-mediated fibrotic 
replacement of graft parenchyma. The second is called chronic vascular rejection and is 
caused by progressive immune-mediated host response to the blood vessels of the solid organ 
graft followed by stenosis of the arteries, arterioles, and capillaries. This process eventually 
leads to replacement fibrosis of the graft parenchyma (Libby and Pober, 2001). This 
progressive luminal narrowing of the graft arteries is frequently seen in cardiac 
transplantation (Julius et al., 2000). It is a multifactorial incident and develops over months to 
years and is only observed in allogeneic but not syngeneic cardiac grafts, demonstrating a 
central role of alloreactivity in the development of these lesions. Since the progressive loss of 
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lumen mainly affects conduit arteries, it can also be called arteriosclerosis, graft 
arteriosclerosis, or transplant vasculopathy (Mitchell and Libby, 2007; Libby and Pober, 
2001). CTV is the main cause of long-term allograft dysfunction and late graft loss in heart 
and kidney transplantation (Nankivell et al., 2003; Weis and von Scheidt, 1997) and it may 
lead to sudden death, myocardial infarction, or dump in cardiac function (Valantine, 2003). 
3.2.3.3 Biology of chronic vascular rejection 
The arterial wall contains three distinct layers (Figure 3: Arterial remodelling in chronic vascular 
rejection (from(Libby and Pober, 2001)).A). The innermost layer, the intima, consists of a 
monolayer of endothelial cells which are positioned on extracellular matrix and occasional 
smooth muscle cells. The intima is situated ablumenally on the internal elastic lamina. The 
next layer is the tunica media and consists of arterial smooth muscle cells within an elastin- 
and collagen-rich extracellular matrix. The next layer is the external elastic lamina. The 
adventitia, the outermost layer of the artery, consists of myofibroblasts, autonomic nerve 
endings, few lymphocytes, and extracellular matrix. 
 
 
 
Figure 3: Arterial remodelling in chronic vascular rejection (from(Libby and Pober, 2001)). 
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Vascular lumen loss in transplant vasculopathy is mostly due to the thickening of the 
intima (Figure 3B), characterized by intimal accumulation of mononuclear cells, particularly 
in the early stage (Salomon et al., 1991), and vascular smooth muscle cells which are both 
mainly host derived (Hillebrands et al., 2001; Shimizu et al., 2001). Furthermore, 
myofibroblasts accumulate and the expansion of extracellular matrix has been observed. As a 
consequence of inflammation at the sites of injury, adhesion molecules such as ICAM-1 and 
VCAM-1 are upregulated on the endothelium (Ardehali et al., 1995), thus leukocytes are 
recruited and colonize the thickened intima of the graft (Hruban et al., 1990; Salomon et al., 
1991; Russell et al., 1994b). The central role of T-cells and EC in the development of CTV 
has been further proven by the significance of the ICAM-1:LFA-1 pathway (Russell et al., 
1995; Russell et al., 1994b). However, it is important that EC are preserved in long-term 
allografts (Rifle et al., 2006) and thus are able to act as on-going targets of an alloresponse. 
Mediators, such as IFN secreted by lymphocytes, mediate further injury and enhance 
extracellular matrix synthesis and MHC class II expression on EC. IFN-blocking with 
monoclonal antibodies clearly demonstrated that IFN is required for the development of 
CTV because lesions did not build up in its absence (Nagano et al., 1997; Nagano et al., 1998; 
Russell et al., 1994d). IFN is mainly produced by activated CD4+ T-cells but also by 
activated CD8
+
 T-cells and macrophages (Munder et al., 1998) that, once they are activated, 
can be significant to maintain an environment where CTV advances (Nagano et al., 1998). 
Further risk factors for CTV development are frequency and severity of acute rejection. In 
addition, differences in MHC and ineffective immunosuppression augment the risk (Isobe et 
al., 2006). Furthermore, nonimmunologic factors, such as the origin of the donor graft from a 
cadaveric donor or diseases like hyperlipidemia, diabetes, hypertension, or high donor age, 
are also known to increase the risk of CTV (Caforio et al., 2004; Kemna et al., 1994; Vassalli 
et al., 2003). In addition, cytomegalovirus infection has been demonstrated to promote CTV 
(Potena and Valantine, 2007; Valantine, 2004). Taken together, these findings confirm the 
overall impact of various vascular wall insults that finally lead to intimal hyperplasia. 
3.2.4 Cytomegalovirus infection 
It is well known that transplant patients undergo immunosuppressive treatment to prevent 
the potent rejection response. As a consequence, an array of side effects, such as defects in the 
control of pathogens (e.g., viral reactivation), can arise. However, accumulating evidence 
supports the hypothesis that viral infections play an imperative role in the pathogenesis of 
solid organ allograft rejection. In clinical and experimental models an association of viral 
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infection has been shown. Most of the studies centred their attention on Cytomegalovirus 
(CMV) as the initiating infectious agent. 
CMV is a ubiquitous herpesvirus which persists in the host. Primary CMV infection is 
frequently asymptomatic. Cells like myeloid lineage cells, smooth muscle cells, and EC are 
crucial sites of CMV replication and latency (Jarvis and Nelson, 2002). In heart transplant 
recipients, CMV infection is a common finding (Potena and Valantine, 2007). Moreover, in a 
mouse model with the closely related murine CMV (MCMV) EC have also been shown to be 
sites of viral latency, particularly small vessels and capillaries harbour the MCMV genome 
(Koffron et al., 1998). Recent studies demonstrate the impact of CMV infection on the 
pathogenesis of allograft rejection, CTV and, long-term graft outcome. CMV-related CTV 
manifests as intimal thickening and constrictive vascular remodelling (Potena et al., 2003). 
Even in the absence of CMV replication, CMV interacts with inflammatory pathways and 
mechanisms of immune-regulation of recipients that subsequently leads to graft damage 
inducing acute and chronic rejection (Potena and Valantine, 2007). It has further been shown 
that only parts of the virus and very low viral burden have the capacity to disrupt the subtle 
equilibrium between graft, host and the immune system (Boehme et al., 2006; Carlquist et al., 
1999; Compton et al., 2003; Tu et al., 2006). Moreover, in rat renal transplant recipients, rats 
with RCMV infection showed significantly reduced renal function measured in serum 
creatinine levels and had considerable inflammatory cell infiltration compared to rats without 
RCMV infection. Furthermore, chemokines, such as RANTES, MCP-1, MIP-1α, and the  
IP-10, were up-regulated (Soule et al., 2006). However, recent studies evaluating the outcome 
of CMV prophylaxis in solid organ recipients demonstrate improved survival and lower 
rejection episodes in patients with anti-CMV treatment (Hodson et al., 2005; Potena et al., 
2006). 
3.2.5 Immunologic mechanisms of chronic vascular rejection 
3.2.5.1 Animal models 
Recent studies of transplantation rejection and its mechanisms have predominantly been 
performed in mice. Although transplantation of hearts or other grafts requires difficult 
microsurgery, the availability of useful reagents, well characterized inbred strains, and 
transgenic mice have made them to become the preferred experimental model. The most 
frequently employed form for heart transplantation at the moment is the heterotopically 
grafting of whole hearts into the abdomen of recipient mice. In these cardiac grafts, the 
ventricular chambers do not fulfil pumping function, although the coronary arteries are 
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perfused. This leads to the development of an intracavitary thrombus. Nevertheless, 
transplantation of allogenic hearts in recipients with MHC disparities induces the 
development of graft arteriosclerosis that resembles human lesions in many characteristics. 
3.2.5.2 The role of CD4+ T-cells 
In chronic rejection, CD4
+
 T-cells are activated by the recognition of alloantigens, mostly 
by the indirect (via host lymphocytes) pathway. It is known that activation of CD4
+
 T-cells 
requires the expression of MHC class II and costimulatory molecules by APC. After 
activation they release proinflammatory cytokines that support the generation of CD8
+
 CTL 
responses and the activation of DC. Cytokines such as TNF, LT and IFNγ, lead to the 
induction of inflammatory infiltrates. Indeed, in the absence of TNF-receptors on the graft, 
CTV has not developed (Suzuki et al., 2003). Furthermore, clearly reduced arterial lesions are 
seen in IFNγ-deficient mice grafted with an allogenic heart graft (Nagano et al., 1997). 
Moreover, the activation state of multiple cell types and the regulation of MHC and 
costimulatory molecule expression is affected by IFNγ. In addition, IFNγ influences the 
production of other cytokines, chemokines and adhesion molecules and the extra cellular 
matrix. However, CD4
+
 T-lymphocytes provide CD4
+
 T-helper functionality by the provision 
of signals that promote differentiation and activation of alloantibody-producing  
B-cells. T-helper cells (Th) activate macrophages unspecifically leading to direct tissue 
damage (Black, 1999; Lowry, 1996). Nonetheless, in the absence of antigen elimination, i.e., 
after transplantation, CD4
+
 T-cells and macrophages stay activated and continue to release 
cytokines which promote the growth of stromal cells and fibrosis which, afterwards, leads to 
chronic rejection (Black, 1999; Salomon et al., 1991). 
3.2.5.3 The role of CD8+ T-cells 
During chronic transplant rejection, donor antigen may be directly presented by donor 
cells, expressing MHC class I molecules, i.e., graft EC, (Biedermann and Pober, 1999; 
Biedermann and Pober, 1998) or it may be cross-presented to CD8
+
 T-cells by host APC, such 
as DC and EC. Cross-presentation of alloantigen by EC has been shown in a mouse model 
with transplanted skin where anti-H-Y monospecific H-2b-restricted MataHari CD8
+
 T-cells 
rejected H-2k male skin grafts on female recipients (Valujskikh et al., 2002a). This indicates 
that donor H-Y antigens are processed and presented by recipient EC and thus, CD8
+
 T-cells 
were activated by a minor histocompatibility difference only. This rejection was clearly  
IFNγ-dependent. However, by their ability of producing IFNγ, CD8+ T-cells support the 
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general inflammatory environment and the activation of leukocytes (Fischbein et al., 2002). 
But their main role in chronic graft rejection is direct cytolysis of parenchymal and vascular 
cells which express MHC class I molecules-donor-antigen-complexes (Rosenberg and Singer, 
1992). CTL are the major effector cells in rejection. This has been confirmed in a mouse 
aortic allograft model where absence of CD8
+
 T-cells in MHC-I knockout recipients, 
prevented the development of chronic rejection (Sun et al., 2001). It is important to point out 
that effector cell triggering occurs in response to any target expressing the particular peptide-
MHC complex. Even very low antigen concentrations are sufficient for their induction while 
activation of CD8
+
 T-cells requires costimulatory signals offered by only a few APC and 
triggering of at least 20-50% of the TCR. (Lassila et al., 1988; Medzhitov and Janeway, Jr., 
1998; Ridge et al., 1998; Valitutti et al., 1996). 
3.2.5.4 The role of CD4+CD25+Foxp3+ regulatory T-cells 
Regulatory T-cells are one of the most powerful mechanisms to induce antigen-specific 
self-tolerance (Joffre et al., 2004). This feature may have important implications for 
transplantation since the induction of alloantigen-specific tolerance would be the treatment of 
choice to evade graft rejection and GVHD. However, in an experimental model transplanted 
allogeneic BM has been protected from rejection by host T-cells via the injection of 
CD4
+
CD25
+
 regulatory T-cells cultured ex vivo (Joffre et al., 2004). In this study specific 
CD4
+
CD25
+
Foxp3
+
 T-cells could be cultivated and expanded in vitro by stimulation with 
host-type APC and in the presence of high IL-2 concentrations and the addition of TGF-β. In 
a subsequent study, CD4
+
CD25
+
Foxp3
+
 regulatory T-lymphocytes could even prevent acute 
and chronic rejection of skin and heart allografts (Joffre et al., 2008). Mice treated with 
clinically acceptable levels of irradiation got long-term tolerance to BM and subsequent skin 
and cardiac allografts after transfer of regulatory T-cells stimulated in vitro with alloantigen. 
Furthermore, acute rejection could be prevented by regulatory T-cells specific for directly 
presented antigen, whereas for the prevention of chronic rejection regulatory T-cells specific 
for both directly and indirectly presented alloantigens had to be used. In the same context, 
Krupnick et al. showed that allogeneic presentation by EC led to the generation of 
CD4
+
CD25
+
Foxp3
+ 
regulatory T-cells (Krupnick et al., 2005). Tolerance induced by 
regulatory T-cells is IFNγ-dependent (Thebault et al., 2007). 
3.2.5.5 The role of endothelial cells in acute and chronic rejection 
The endothelium had been seen for a long time as a simple passive layer within the vessel 
wall. Now it is known to be engaged in physiologic and pathophysiologic immune processes, 
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such as atheriosclerosis, autoimmune diseases, inflammation, and allograft rejection (Briscoe 
et al., 1998b; Gimbrone, Jr. et al., 2000; Salmi et al., 1993; Wick et al., 1997). It is of major 
importance in maintaining normal vessel wall function; it controls thrombus building, 
leukocyte adhesion, the proliferation of vascular smooth muscle cells, and regulates the vessel 
tonus. 
EC build the inner lining of graft vessels and are therefore the first graft cells encountered 
by host lymphocytes in solid organ transplantation. By promoting both the recruitment and 
the activation of alloreactive T-cells they participate in the process of allograft rejection 
(Valantine, 2003; Wick et al., 1997). Furthermore, they are exposed to multiple events that 
provoke EC injury which could subsequently initiate local vascular events, known as CTV. 
After activation, T-cells are recruited to the peripheral tissue and thereby have to 
transmigrate through monolayers of vascular EC. The recruitment of activated T-cells from 
the blood to the site of inflammation is a multistep process regulated by leukocyte/EC 
interaction (Butcher and Picker, 1996). It starts with the rolling of T-lymphocytes along the 
endothelium, which is mediated by EC-expressed selectins, such as E- and P-selectin 
interacting with L-selectin expressed on leukocytes (Rao et al., 2007; Schon et al., 2002). 
Afterwards, leukocytes use integrins, such as LFA-1, MAC-1, and VLA-4, to interact with 
EC-expressed ligands including ICAM-1 and VCAM-1 to achieve adherence (Butcher and 
Picker, 1996; Nelson and Krensky, 2001). The expression of integrins on leukocytes can be 
regulated in part by EC-secreted chemokines, whereas their expression seems to be mainly 
dependent on IFNγ produced by T-cells (Kobayashi et al., 2003). Interaction with VCAM-1 
and ICAM-1 on graft EC leads to the entry of activated T-cells into the allograft by 
transendothelial cell migration (Campbell et al., 1998). It has been shown that T-cell 
transmigration through the EC barrier changed their surface markers and their ability to 
migrate. Furthermore, the avidity for the allogeneic stimulators became higher which 
influenced the effector function of T-cells infiltrating into the graft (Denton et al., 1999). 
However, resting EC express MHC class I molecules and low levels of costimulatory 
molecules, such as CD80 (B7-1), on their surface. In the presence of inflammatory cytokines, 
for instance IFNγ, MHC class II expression can be induced and the expression of MHC class I 
molecules may be upregulated, whereas CD80 expression is not changed (Marelli-Berg et al., 
2000; Pober et al., 1997; Rose, 1998; Russell et al., 1994d). This phenomenon enables EC in 
vitro to act as APC which has been demonstrated via isolated mouse EC presenting an 
alloantigen triggering alloreactive CD8
+
 T-cells to become potent cytotoxic and IFNγ-
secreting effector cells but not CD4
+
 T-cells (Kreisel et al., 2002a; Ma and Pober, 1998). 
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Stimulation of CD8
+
 T-cells has also been induced after culture with resting endothelium 
(Kreisel et al., 2002a). This direct activation is B7-dependent since T-cell proliferation was 
inhibited by CTLA4-lg which blocks CD28 costimulation (Kreisel et al., 2002a). Besides, 
human resting CD8
+
 T-cells could also be directly activated by alloantigen presenting EC in 
vitro (Epperson and Pober, 1994). CD4
+
 T-cells proliferated only when cultured with IFNγ 
treated allogeneic EC since thereby the expression of MHC class II molecules was induced 
(Pober et al., 1997). Kreisel et al. additionally provided in vivo evidence of priming naive 
alloreactive CD8
+
 T-cells through non-hematopoietic allograft cells leading to acute rejection 
(Kreisel et al., 2002b). In this chimeric transplantation model alloantigens were expressed on 
graft EC but not on graft-derived hematopoietic cells. These facts suggest that EC may have 
the potential to stimulate naive allogeneic T-cells, particularly when no other alloactivation is 
present. Taken together, these data clearly show that vascular EC can act as APC to allogeneic 
CD8
+
 T-cells and can trigger allograft rejection via CD8
+
 direct allorecognition. This is of 
main significance considering that EC are present for the life span of the allograft and thus 
contribute to the progress of chronic rejection. Whether nonhematopoietic cells, such as 
vascular EC, possess the ability to activate alloreactive CD4
+
 T-cells, has been controversially 
discussed for a long time. An in vivo study by Kreisel et al. finally displayed that vascular 
endothelium could not activate CD4
+
 T-cells via direct allorecognition, even when EC were 
cytokine-activated and MHC class II molecules expression was induced. In this study, hearts 
that express MHC class II and hearts which lack MHC class II on hematopoietic cells were 
transplanted. Both types were acutely rejected, but with significant delay in the latter case, 
regardless of the expression of MHC class II on graft EC (Kreisel et al., 2004). 
Further data from a minor histocompatibility disparate model showed that murine lung EC, 
loaded with peptide, could induce proliferation of CD8
+
 T-cells but they lose their 
immunogenicity following IFNγ treatment and become tolerogenic towards CD8+ T-cells in 
vitro. They further failed to induce a proliferative response in CD4
+
 T-cells, although EC 
expressed CD80 molecules and expression of MHC class II molecule was induced, and MHC 
class I upregulated (Marelli-Berg et al., 2001). In contrast, activated and peptide-pulsed EC 
were indeed killed more efficiently by effector CD8
+
 T cells (Marelli-Berg et al., 2000).  
Furthermore, several in vitro and in vivo studies confirmed that cognate interaction 
between naive T-cells and resting EC, considered as non-professional APC, leads to  
CD8
+
 T-cell tolerance (Limmer et al., 2000; Marelli-Berg et al., 2000; Perez et al., 1998). 
Also cross-presentation of oral antigens or antigens from apoptotic tumour cells by LSEC lead 
to specific CD8
+
 T-cell tolerance (Berg et al., 2006; Limmer et al., 2005). The ability of EC to 
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cross-present antigens in the context of transplantation has been demonstrated by a study of 
Bagai et al. showing that cultured murine aortic EC are able to process and present MHC-I-
restricted antigen (Bagai et al., 2005a). 
In addition, a recent in vitro study displayed CD4
+
CD25
+
Foxp3
+
 regulatory T-cell 
induction by EC leading to the inhibition of T-cell proliferation. This process was 
independent of CD80 costimulation but dependent on PD-L1 (Krupnick et al., 2005).  
However, only a few studies assessed the role of EC-CTL interaction in vivo, and whether 
EC tolerize or activate naive T-cells is a matter of further investigations. Although, the 
diverse settings of the different studies, such as dissimilar sources and activation states of EC, 
different affinities of T-cells and the use of nominal versus alloantigen, may be explanations 
for the partially contradictory results, one could summarize and conclude as follows: First, in 
the context of alloantigens (major histocompatibility antigen), CD8
+
 T-cells have been shown 
to become activated via resting EC in vitro and in vivo, whereas CD4
+
 T-cells become 
activated only via activated EC in vitro but not in vivo. Second, in the context of a nominal 
antigen (minor histocompatibility antigen), EC can induce CD8
+
 T-cell proliferation in vitro, 
whereas activated EC fail to induce CD8
+
 and CD4
+
 T-cell in vitro and in vivo, and there is 
indeed rather induction of T-cell tolerance. 
However, the fact that EC constitutively express MHC-I molecules and MHC-II molecules 
expression is inducible, make them susceptible to cellular and humoral host immune 
reactions. They are target cells for activated alloreactive CTL during GVHD which is 
characterized by the circulation of a large number of mhAg-specific CTL (Biedermann et al., 
2002; Mutis et al., 1999). Alloantigen-specific CD8
+
 T-cells directly recognize peptide-donor-
MHC molecules complexes on EC and kill them. Apoptosis of EC induced by cytotoxic CD8
+
 
T-cells is a key initiating event in the development of CTV. It leads to the contact to the 
subendothelial matrix and thus, to the enhancement of the inflammatory response. At sites of 
EC injury mononuclear leukocytes are recruited. Because of their production of biologically 
relevant molecules, they favour the accumulation and proliferation of vascular smooth muscle 
cells. This leads to neointima formation and at a later time point to ischemic graft loss. It has 
been shown, that it is mainly a perforin-dependent process since perforin-deficient CTL failed 
to destroy EC in culture. Interestingly, the deficiency in Fas/FasL had only a minor impact 
(Krupnick et al., 2002). Furthermore, Valujskikh et al. could provide evidence, that EC have 
the ability to process antigenic proteins derived from exogenous sources and present them to 
recipient CD8
+
 T-cells on recipient MHC I molecules. T-cells that recognized cross-presented 
antigen mediated skin-graft rejection (Valujskikh et al., 2002a). In vitro studies by Marelli-
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Berg et al. demonstrated the ability of CD8
+
 cytotoxic T-cells to lyse cytokine-treated EC 
presenting a mhAg (Marelli-Berg et al., 2000; Marelli-Berg et al., 2001). And, in a heart 
transplantation mouse model of CTV with minor histocompatibility disparity, perforin 
knockout recipient mice as well as granzyme B knockout recipients, had indeed comparable 
levels of T-cell infiltration but less endothelial apoptosis and therefore less fibroproliferative 
changes (Choy et al., 2004b; Choy et al., 2004a). Apoptotic EC were also shown in coronary 
arteries of human transplants mounting early signs of CTV (Dong et al., 1996b; Dong et al., 
1996a) confirming T-cell induced endothelial injury being a central event in the development 
of CTV. 
Moreover, activated EC play a major role in the coagulation process supporting 
coagulation and platelet aggregation. In addition, vascular endothelial growth factor (VEGF) 
and platelet-derived growth factor (PDGF) are proinflammatory factors in the transplantation 
setting and help to develop CTV (Nykanen et al., 2006). This is of significant importance 
since they precipitate endothelial cell injury, which induces platelet adhesion and the release 
of growth factors and leads to the subsequent development of CTV.  
Taken together, these data indicate the importance of EC in the development of acute and 
chronic rejections. And there is increasing evidence implying that EC are key players in the 
process of chronic rejection. 
3.2.6 Therapy of allograft rejection 
Immune responses directed against allografts are mainly orchestrated by T-cells that 
become activated after recognizing alloantigens and appropriate costimulatory signals. Since 
stimulation through TCR without costimulation leads to T-cell anergy (Schwartz, 1990), the 
blockade of T-cell costimulation provides an attractive target for therapies aimed at limiting 
acute rejection. In addition to the use of drugs, such as cyclosporine which reduces the T-cell 
response, or other macrolide immunosuppressants, such as rapamycin, the use of reagents that 
block costimulatory signals show promising results in preventing the acute rejection response 
(Khoury et al., 1999). Furthermore, the use of rapamycin together with anti-CD40L therapy 
promotes long-term allograft survival whereas cyclosporine, tacrolimus, and IL-2R 
monoclonal antibody therapy abolish the outcome of CD40L-block (Sho et al., 2002).  
3.2.7 Tolerance induction in transplantation 
Although the presence of effective immunosuppressive drugs prevents acute rejection, 
many of the standard drugs inhibit T-cell signalling and therefore inhibit the active process of 
tolerance induction, which is the treatment of choice in allograft rejection and GVHD. 
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Currently, different ways to induce specific T-cell tolerance are assessed, including co-
stimulatory blockade, introduction of chimersim, the use of CD4
+
CD25
+
Foxp3
+
 regulatory  
T-cells, and the combination of those.  
However, one of the best characterized and most important costimulatory pathways is the 
CD28/CTLA4:CD80/CD86 pathway (Salomon and Bluestone, 2001). These costimulatory 
molecules belong to the B7 family. CD28 is constitutively expressed on T-cells whereas 
CD86 molecules are expressed at low levels by resting professional APC. CD80 and CD86 
are both upregulated on activated professional APC. Their interaction induces full T-cells 
activation including cytokine production (Rothstein and Sayegh, 2003) while the interaction 
of CTLA-4, a molecule similar to CD28 but only expressed after cellular activation, delivers a 
negative signal, resulting in T-cell inhibition (Sharpe and Freeman, 2002). However, it has 
been demonstrated that the blockade of this pathway by CTLA-4lg, induced donor specific 
tolerance in several experimental models (Lin et al., 1993; Pearson et al., 1994; Pearson et al., 
1996; Sho et al., 2002). Deficiency in CD80/CD86 even resulted in xenograft survival 
(Hosiawa et al., 2005).  
A further target is the costimulatory CD40L:CD40 pathway. It consists of the CD40 and 
the CD40L molecules that belong to the TNFR and TNF super families, respectively. CD40 is 
a cell surface molecule that is expressed on several cell types including most professional 
APC (Grewal and Flavell, 1998). CD40 is also expressed on EC and therefore mediates their 
activation responses (Hollenbaugh et al., 1995). CD40L is expressed on activated T-cells, as 
well as on other cell types, such as activated B-cells and DC (Grewal and Flavell, 1998), and 
activates expression of adhesion molecules and cytokines in EC (Hollenbaugh et al., 1995; 
Karmann et al., 1995). However, it has been demonstrated that CD40 signalling is important 
in T-cell-mediated immunity where it induces the expression of co-stimulatory molecules and 
cytokines, such as CD80,CD86, ICAM-1, IL-1, and IL-12 on APC (van Essen et al., 1995), 
and upregulates MHC I and MHC II expression to turn the APC a more effective APC. 
Furthermore, CD40L:CD40 interaction activates antigen-specific T-cells to proliferate and 
secrete cytokines (Grewal et al., 1995; Grewal et al., 1996). The lack of CD40L in mice 
infected with lymphocytic choriomeningitis virus (LCMV) did not influence the virus-specific 
CD8
+ 
T-cell response but the virus-specific CD4
+
 T-cell response was rigorously 
compromised (Whitmire et al., 1999). Blockade of both pathways can prevent allograft 
rejection (Kirk et al., 1997). Nevertheless, although promising results are seen in many 
experimental models, the blockade of these pathways does not completely control rejection 
(Guo et al., 2001; Jones et al., 2000). This indicates that not all alloreactive T-cells depend on 
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these costimulatory signals. For example, primed allospecific T-cells or alloreactive CD4
+
 
memory T-cells act independently and circumvent CD40:CD40L costimulation (Chen et al., 
2004; Valujskikh et al., 2002b).  
A further pathway consisting of molecules belonging to the B7 family is the  
PD-1:PD-L1/PD-L2 pathway. PD-L1 and PD-L2 are expressed by a broader range of cells. 
Additionally to its expression on professional APC, PD-L1 is also expressed by vascular EC 
where it is upregulated in response to IFNγ and TNF (Eppihimer et al., 2002; Rodig et al., 
2003). It is involved in the suppression of the T-cell cytokine synthesis which is proportional 
to the primary stimulus (Mazanet and Hughes, 2002). In contrast to PD-L1, PD-L2 is 
restricted to hematopoietic APC, such as DC and macrophages (Latchman et al., 2001). Both 
are ligands of PD-1 which transduces inhibitory signals and is induced on peripheral T-cells, 
B-cells, and myeloid cells upon activation (Agata et al., 1996). However, it has been shown 
that expression of PD-L1 is important for peripheral control of autoreactive T-cells (Keir et 
al., 2006). In a model where CD8
+
 T-cell myocarditis could be induced by transfer of OT-I 
CTL into mice which express membrane-anchored Ova exclusively in cardiac myocytes, 
IFNγ-induced PD-L1 on cardiac EC played a major role in preventing inflammatory injury to 
the myocardium (Grabie et al., 2007). Further studies have assessed the role of PD-1 and its 
ligand in murine cardiac allograft rejection and have shown that treatment with blocking anti-
PD-1 antibody aggravate acute cardiac allograft rejection. Agonists, used with 
immunosuppressive drugs, improved acute cardiac rejection and CTV (Ito et al., 2005; 
Ozkaynak et al., 2002). In a very recent study PD-1:PDL1 interaction acquired transplantation 
tolerance. Indeed, using blocking antibodies against PDL1 demonstrated that recipient but not 
donor PDL1 is necessary to acquire tolerance induction and maintenance after CTLA-4lg 
therapy (Tanaka et al., 2007). These data provide evidence for the major role of PD-1:PDL1 
interaction in peripheral tolerance induction after transplantation by limiting the expansion of 
alloreactive T-cells. Taken together, it is the integration of positive and negative 
costimulatory signals that finally decides on the outcome of a T-cell response. 
Following transplantation of a solid organ allograft donor microchimerism can occur. Such 
rare cases of donor microchimerism are associated with long-term acceptance of the organ, 
therefore microchimerism is thought to play an active role in the induction of 
unresponsiveness (Ehl et al., 1998a; Cosimi and Sachs, 2004; Millan et al., 2002; Monaco, 
2002; Wood and Sachs, 1996). However, chimerism has been shown to be a tool to induce 
specific transplantation tolerance (Claas, 2004). This has been confirmed in a study by Bonilla 
et al, demonstrating that microchimerism induced active clonal deletion of donor cell-specific 
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T-cells (Bonilla et al., 2006), and identifying the induction of chimerism as a specific and 
effective way to prevent transplant rejection. 
Furthermore, the combination of chimerism with the adoptive transfer of 
CD4
+
CD25
+
Foxp3
+
 regulatory T-lymphocytes prevented acute and chronic allograft rejection 
in a skin and heart transplantation mouse model in vivo (Joffre et al., 2008). The combination 
of both methods may be a way to reduce the toxicity of previous irradiation in BM 
transplantation and may be a promising protocol acceptable in clinical settings. 
Despite hopeful results for the therapy in acute rejection and the fact that acute rejection 
can be prevented by immunosuppressive drugs, chronic rejection still occurs. While the 
number of patients that survive up to one year after transplantation continues to increase, the 
percentage of long term survival has not changed significantly over the past 20 years (Taylor 
et al., 2005). There is indeed a current lack of effective preventive therapies for chronic 
rejection. On the one hand, actual therapies may not be able to ameliorate the problems of 
chronic rejection because they target the wrong mechanisms. On the other hand, since the 
fundamental basis of chronic rejection is not well understood, it is obvious that the current 
drugs do not solve the problem. A more targeted immunosuppressive treatment may be a step 
in this direction. Therefore, the diffuse nature of chronic vascular rejection has to become 
clearer. Any plan that can limit immune or nonimmune injury to the vessels should help 
hinder graft vasculopathy.  
Consequently, the mechanism underlying acute and chronic rejection, particularly the 
detailed interaction between donor and host APC and recipient leucocytes, has to be 
investigated, with the aim to reach a more specific therapy to prevent allograft rejection.  
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3.3 A transgenic model to investigate the cognate interaction of CD8+  
T-cells with vascular endothelial cells expressing a minor 
histocompatibility antigen 
Transgenic techniques are powerful tools to set up models with microbial antigens present 
in specific tissues and therefore facilitate the targeting of antigens to, for example, vascular 
EC. Antigen transgenic mice combined with the use of TCR transgenic animals have been 
shown to provide essential insight into the basic principle of immunology, such as 
autoimmunity (Ohashi et al., 1991; von Herrath and Oldstone, 1996), and tumour immunity 
(Morgan et al., 1998; Speiser et al., 1997). To study the role of EC in presenting a mhAg in 
vivo, two different lines of transgenic mice that express bacterial -gal exclusively on the 
vascular endothelium exist. In VWF-LacZ mice the expression of -gal in EC is restricted to 
the heart and the brain (Aird et al., 1995; Aird et al., 1997). In Tie2-LacZ mice, a portion of 
the promoter and first intron of the gene encoding tie2, the receptor for the vascular 
differentiation factor angiopoietin-1, drives the expression of -gal antigen in EC in all organs 
(Schlaeger et al., 1997). In the studies hereafter, Tie2-LacZ mice, backcrossed to the C57BL/6 
background were used. In Tie2-LacZ mice, cells remain in their physiological setting and 
transgene expression avoids inflammation, therefore they are ideal in order to investigate 
antigen presentation by EC in vivo and to gain insight into the basic mechanisms initiating 
chronic vascular rejection. Furthermore, the use of recent transgenic models, facilitating the 
specific ablation of CD11c-positive DC in lymphoid organs (CD11c-DTR-mice) (Jung et al., 
2002), and the use of naturally occurring mutants, exhibiting a mutated H2-K
b
 molecule that 
precludes H2-K
b
-restricted presentation of peptides (B6.C-H2
bm1
-mice), allowed dissecting 
the role of professional versus non-professional APC. Additionally, in vivo analysis of 
antigen-specific interaction between EC and CD8
+
 T-cells has been eased by using high 
affinity β-gal specific TCR transgenic CD8+ T-cells (Bg1-cells). To assess the cognate 
interaction of EC with activated CTL in a transplantation model, where Tie2-LacZ and 
control C57BL/6 hearts were heterotopically transplanted into C57BL/6 recipients, the 
repetitive priming of recipients with DC presenting an H-2K
b
-restricted peptide derived from 
β-gal, induced activation of β-gal specific CD8+ T-cells for more than two weeks and enabled 
the investigation of EC interaction with activated CD8
+
 T-cell in a chronic setting. 
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4 Aims of the study 
The significance of chronic inflammatory processes in the pathogenesis of cardiovascular 
diseases is widely known. Atherosclerosis and autoimmune myocarditis are prototypic 
diseases demonstrating the unfavourable effect of constant immune activation within the 
cardiovascular system. Likewise, chronic rejection of solid organ transplants is characterized 
by a constant immune activation within the blood vessels of the transplanted organ. Despite 
the success in the treatment of acute rejection with immunosuppressive drugs, late graft 
rejection of a major organ (heart, liver, and kidney) occurs at a rate of 3-5% per year post 
transplantation (Cecka, 1999; Keck et al., 1999). Constant inflammation during chronic 
rejection results in a persistent activation of both helper and cytotoxic T-cells. It is likely that 
these inflammatory processes are driven through chronic antigen presentation within the 
blood vessel wall, by both professional APC (DC, macrophages and B cells) and non-
professional APC (e.g. EC). The detailed characterization of the interaction of CD8
+
 T-cells 
with professional and non-professional APC would be a major issue helping to delineate the 
exact mechanisms underlying vascular rejection of solid organ transplants. 
EC act as the major interface between blood and tissue. In the context of transplantation 
they fulfil important functions, including regulation of host leukocyte trafficking into the graft 
parenchyma, activation of the recipient lymphocytes, transmission of signals to other vascular 
cells, and angiogenesis reactions that develop during the healing process. Moreover, the 
vascular endothelium is a dynamic structure that contributes to the inflammatory response by 
the synthesis and display of various surface receptors and soluble molecules. Therefore, we 
hypothesized that the direct interaction of EC with T-cells is a critical factor for the activation 
or possible tolerization of T-cells. 
A first specific aim of our study was to analyze the interaction of EC with CD8
+
 T-cells in 
Tie2-LacZ mice in vivo. Using BM chimeric mice, we determined whether there is a direct 
interaction of β-gal specific CD8+ T-cells with β-gal-expressing EC or whether β-gal peptides 
are cross-presented by BM derived APC. 
In the second part of this study, we wanted to develop an experimental system that 
facilitates in vivo analysis on the cognate interaction of EC with activated CTL in a 
heterotopic heart transplantation model. Such a model should enable dissection of the 
immunologic mechanisms underlying the vascular rejection of Tie2-LacZ hearts transplanted 
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in C57BL/6 recipients. Furthermore, the role of persistent MCMV infection of transplant 
recipients for the acceptance of heart grafts was explored. 
We expect to provide a detailed study of the factors influencing the decision making 
process between T-cell activation versus T-cell tolerization in the context of chronic vascular 
rejection of solid organ grafts. In the long-term, we want to analyze the factors that influence 
EC-CTL interaction. These insights into the basic immunological mechanisms underlying 
chronic inflammatory processes may permit the evaluation of treatment strategies that could 
help to specifically tone-down the harmful consequences of chronic immune activation in 
chronic vascular rejection. 
 
 
Figure 4: Do vascular EC that present a minor histocompatibility antigen activate or tolerize naive CD8
+
  
T-cells? 
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5 Results  
5.1 Immunologic ignorance of vascular endothelial cells expressing 
minor histocompatibility antigen 
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5.1.1 Abstract  
Endothelial cells (EC) presenting minor histocompatibility antigen (mhAg) are major 
target cells for alloreactive effector CD8
+
 T-cells during chronic transplant rejection and 
graft-versus-host disease (GVHD). The contribution of EC to T-cell activation, however, is 
still a controversial issue. In this study, we have assessed the antigen presenting capacity of 
EC in vivo using a transgenic mouse model with beta-galactosidase (-gal) expression 
confined to the vascular endothelium (Tie2-LacZ mice). In a GVHD-like setting with 
adoptive transfer of -gal-specific T-cell receptor transgenic T-cells, -gal expression by EC 
was neither sufficient to activate nor to tolerize CD8
+
 T-cells. Likewise, transplantation of 
fully vascularized heart or liver grafts from Tie2-LacZ mice into non-transgenic recipients did 
not suffice to activate -gal-specific CD8+ T-cells, indicating that CD8+ T-cell responses 
against mhAg cannot be initiated by EC. Moreover, we could show that spontaneous 
activation of -gal-specific CD8+ T-cells in Tie2-LacZ mice was exclusively dependent on 
CD11c
+
 dendritic cells (DC) demonstrating that mhAg presented by EC remain 
immunologically ignored unless presentation by DC is granted.  
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5.1.2 Introduction 
Endothelial cells act as the major interface between blood and tissues. Forming the inner 
lining of blood vessels, they are uniquely positioned between circulating lymphocytes and the 
periphery and thereby regulate the trafficking of T-lymphocytes from the bloodstream to sites 
of infection and inflammation. Following transplantation of vascularized organs, EC are the 
first graft cells encountered by activated host lymphocytes and are therefore primary targets of 
alloreactive CTL (Briscoe et al., 1998a; Libby and Pober, 2001). Since donor EC persist in 
vascularized organ transplants, they may contribute to chronic immune stimulation and 
thereby fuel the process of chronic rejection. Such late graft failure is a major problem in 
transplantation medicine that frequently necessitates retransplantation (Weis and von Scheidt, 
1997). Furthermore, EC are important target cells for activated alloreactive CTL during graft 
versus host disease (GVHD) (Biedermann et al., 2002) which is characterized by large 
numbers of circulating minor histocompatibility antigen (mhAg)-specific CTL (Mutis et al., 
1999). 
EC can act as antigen presenting cells (APC) to CD8
+
 T-cells both via the direct pathway 
(i.e. recognition of allo-MHC:peptide complexes) or via the indirect pathway involving cross-
presentation of exogenous antigens (Valujskikh et al., 2002a; Bagai et al., 2005b; Limmer et 
al., 2000). In vitro studies have demonstrated that both human (Epperson and Pober, 1994) 
and murine (Kreisel et al., 2002a) EC can activate resting allogeneic CD8
+
 T-cells suggesting 
that EC critically contribute to the initial stimulation of alloreactive T-lymphocytes (Briscoe 
et al., 1998a). Moreover, EC exhibit important functions of professional APC including 
expression of MHC class II and costimulatory molecules (Rose, 1998) and cross-presentation 
of mhAg (Valujskikh et al., 2002a; Limmer et al., 2000). The notion that EC may under 
particular circumstances act as professional APC has been supported by the finding that non-
hematopoietic cells within vascularized grafts - presumably EC - are able to initiate CTL 
responses that mediate allograft rejection (Kreisel et al., 2002b).  
There are, however, a number of reports challenging the view that EC may act as immune 
activators. Murine lung EC, for example, have been shown to negatively regulate CD8
+
 T-cell 
function (Marelli-Berg et al., 2000). Furthermore, liver sinusoidal EC can induce CD8
+
 T-cell 
tolerance to soluble (Limmer et al., 2000; Limmer et al., 2005) or tumour-derived antigens 
(Berg et al., 2006). A third possible form of EC-CTL interaction is that of immunological 
ignorance. Indeed, aly/aly mice lacking secondary lymphoid organs fail to reject vascularized 
organ transplants, even in an allogeneic setting (Lakkis et al., 2000) suggesting that the 
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environment of organized lymphoid tissues is critical for primary activation of T-cell 
responses. To a large extent the above-mentioned contradictory findings can be explained by 
the use of in vitro co-culture systems or the lack of an appropriate in vivo model with truly 
EC-restricted antigen presentation. An experimental in vivo system with expression of well-
defined antigens exclusively in vascular EC may therefore be helpful to solve the question 
whether antigen presentation by vascular EC can lead to activation or tolerization of antigen-
specific CD8
+
 T-cells.  
The use of antigen-transgenic mice combined with the power of TCR transgenic animals 
has provided important insight into the basic principles of autoimmunity (Ohashi et al., 1991; 
von Herrath and Oldstone, 1996), and tumour immunity (Morgan et al., 1998; Speiser et al., 
1997). Recently, similar systems have been exploited to analyze T-cell responses in different 
allograft transplantation (Kreisel et al., 2004; Valujskikh et al., 2002a; Valujskikh et al., 2006; 
Ford et al., 2007) and GVHD models (Ehl et al., 1998b). However, despite significant 
advances in our understanding of the antigen presenting function of non-hematopoietic cells 
during allograft reactions (Kreisel et al., 2004) or the importance of T-cell frequencies for 
solid organ graft rejection (Ford et al., 2007; He et al., 2004b), the precise role of mhAg 
presentation by EC has remained elusive. We have used here Tie2-LacZ mice to model mhAg 
presentation by EC. In these mice, the tie2 promoter drives the expression of the beta-
galactosidase (-gal) antigen in EC in all tissues (Schlaeger et al., 1997). In vivo analysis of 
antigen-specific interaction between EC and CD8
+
 T-cell has been facilitated by using high 
affinity -gal-specific TCR transgenic CD8+ T-cells (Bg1 cells). Adoptive transfer of Bg1 
CD8
+
 T-cells into Tie2-LacZ mice revealed that mhAg presentation by EC did not suffice to 
activate or to tolerize CD8
+
 T-cells. Furthermore, -gal expression by EC in heterotopically 
transplanted Tie2-LacZ hearts or orthotopically transplanted Tie2-LacZ livers did not result in 
CD8
+
 T-cell activation in naive recipients. Finally, generation of bone marrow (BM) chimeric 
mice that facilitated selective ablation of CD11c-positive dendritic cells (DC) revealed that 
EC-associated mhAg has to be cross-presented by DC in order to elicit CD8
+
 T-cell 
activation.  
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5.1.3 Materials and Methods 
Mice 
Male and female C57BL/6 mice were obtained from Charles River (Sulzfeld, Germany). 
Tie2-LacZ mice (Schlaeger et al., 1997) had been backcrossed with C57BL/6 for at least 14 
times. B6.C-H2
bm1
 mice were provided by Christian Kurts (University of Bonn, Germany). 
Bg1 mice were produced with TCR cassette vectors generously provided by Dr Diane Mathis 
(Brigham and Women's Hospital, Boston, MA). RNA was isolated from a β-gal96–103-specific 
CD8
+
 T-cell clone, generated by limiting dilution, using silica matrix columns (Qiagen, 
Valencia, CA). Known TCR α and β constant region sequences were used to perform 5′ rapid 
amplification of cDNA ends (Invitrogen, Carlsbad, CA), and TCR sequences were then 
cloned into pCR4TOPO TA cloning sequencing vectors (Invitrogen). The TCR α and β 
transcripts were sequenced using an ABI Prism (Perkin-Elmer, Wellesley, MA), and these 
sequences were compared with available sequences to develop genomic cloning polymerase 
chain reaction (PCR) primers. These cloning primers provide amplification of the variable 
domains consisting of 10–20 bp upstream of the start codon through 200–300 bp of intronic 
sequence downstream of the junctional regions, thereby preserving splice donor/acceptor 
sites. The α and β genomic variable domains were PCR-amplified (Perkin-Elmer) and TA-
cloned into a sequencing vector (Invitrogen). The genomic variable domains were sequenced 
(Vα1/JαTA13/Cα and Vβ7S1/Jβ2S4/Cβ2) and subcloned into the TCR cassette vectors. The α 
and β cassette vectors were coinjected into fertilized C57BL/6 embryos (SAIC, Frederick, 
MD) and founders were obtained. The resulting mice, named Bg1, were maintained as 
heterozygotes, as a high rate of lymphoma in homozygotes reduced their life span. 
Heterozygotes were bred to B6.SJL mice and transgene expression was monitored by staining 
of blood cells with anti-Vβ7 by flow cytometry. Bg1 mice were further crossed with C57BL/6 
mice expressing the congenic marker Thy 1.1. Mice expressing the human high affinity 
diphteria toxin receptor (DTR) under the control of the CD11c promoter (Jung et al., 2002) 
were provided by Steffen Jung (The Weizmann Institute of Science, Rehovot, Israel). The 
presence of the gal and DTR transgenes was determined by PCR from genomic DNA; the 
presence of the H2-K
bm1
 molecule was determined by flow cytometry of blood lymphocytes 
using the 5F1 antibody (Sherman and Randolph, 1981). All animals were kept under 
conventional conditions in individually ventilated cages and fed with normal chow diet. 
Experiments were carried out with age (6-8 weeks) and sex-matched animals. Experiments 
were performed in accordance with Swiss Cantonal and Federal legislations.  
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Viruses and peptides 
Recombinant MCMV expressing the -gal protein under the transcriptional control of the 
human CMV ie1/ie2 promoter-enhancer (MCMV-LacZ RM427 (Manning and Mocarski, 
1988)) was kindly provided by Prof. E. S. Mocarski (Stanford University, San Francisco). 
MCMV-LacZ was propagated and titrated on NIH 3T3 cells (ECACC, UK) and injected 
intravenously at a dose of 2106 pfu. -gal96-103 (DAPIYTNV) (Overwijk et al., 1997),  
-gal497–504 (ICPMYARV) (Oukka et al., 1996) and MCMV M45985-993 (HGIRNASFI) (Gold 
et al., 2002) peptides were purchased from Neosystem (Strasbourg, France). 
 
Generation of bone marrow chimeric mice 
Recipient mice were lethally irradiated with 900 rads from a linear accelerator (clinics of 
radio-oncology, Cantonal Hospital St. Gallen) and intravenously injected 1 day later with 
2107 of the indicated donor BM cells. Chimeric mice were maintained on antibiotic water 
containing Sulfadoxin and Trimethoprim (Borgal, Veterinaria AG, Zurich, Switzerland) for 
the following 3 weeks. Recipient mice carrying the K
bm1
 mutation, received CD4
+
- and  
CD8
+
-T-cell-depleted BM and were further depleted of NK 1.1
+
 cells by i.p. injection of 20 l 
anti-asialo GM1 antibody (Wako Pure Chemical Industries, Ltd.) on the day before and in 
weekly intervals for 6 wk following irradiation. Mice were used for experiments 8 to 10 
weeks after bone marrow reconstitution. 
 
Antibodies and flow cytometry 
Anti-CD8-FITC, anti-CD4-PerCP, anti-V7-FITC, anti-CD90.1-PE, anti-CD44-PE, and 
anti-IFNγ-PE were obtained from BD PharMingen (Basel, Switzerland). Anti-CD8-APC was 
obtained from Biolegend (LuBioScience GmbH, Lucerne, Switzerland). Anti-CD62L-PE was 
obtained from ImmunoTools (Friesoythe, Germany). For flow cytometry, single cell 
suspensions were generated from the indicated organs and 1×10
6
 
cells were incubated with the 
indicated mAb at 4°C for 20 min. For PBL samples, erythrocytes were lysed with FACS 
Lysing Solution (BD PharMingen). Cells were analyzed with a FACScalibur flow cytometer 
using the CellQuest software (BD Biosciences). The cells were analyzed by flow cytometry, 
gating on viable leukocytes using 7-aminoactinomycin D (Sigma). 
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Construction of tetrameric MHC class I-peptide complexes and flow cytometry 
MHC class I monomers complexed with -gal (H-2Kb) or M45 peptides (H-2Db) were 
produced as previously described (Altman et al., 1996) and tetramerized by addition of 
streptavidin-PE (Molecular Probes, Eugene, OR). At the indicated time points following 
infection, organs were removed and single cell suspensions were prepared. Aliquots of 5106 
cells or 300 l of blood were stained using 50 l of a solution containing tetrameric  
class I-peptide complexes at 37°C for 10 min followed by staining with anti-CD8-FITC (BD 
Pharmingen) at 4°C for 20 min. Absolute cell counts were determined by counting leukocytes 
in an improved Neubauer chamber. 
 
Chromium release assay 
EL-4 cells pulsed with peptide or without peptide (negative control) were used as target 
cells in a standard 
51
Cr release assay. Cells were labelled with 200 Ci 51Cr (EGT Chemie, 
Tägerig, Switzerland) for 1 h at 37°C. A total of 10
4
 target cells/well were incubated for 5 h in 
96-well round bottom plates with 3-fold serial dilutions of effector cells. Splenocytes from 
MCMV-LacZ infected mice that were restimulated with the indicated peptides for 5 days 
were tested for their cytolytic activity. Spontaneous chromium release was always below 
15%. 
 
CFSE labelling of TCR transgenic T cells and adoptive transfer 
Single cell suspensions from spleens of Bg1 mice were subjected to hypotonic red blood 
cell lysis and stained with CFSE (Molecular Probes, Leiden, The Netherland). A maximum 
concentration of 2.5107 cells/ml were incubated in 5 M CFSE in PBS for 10 min at 37°C. 
Cells were washed twice with ice-cold BSS and resuspended in BSS at a concentration of 
1.5107 splenocytes/ml. Recipient C57BL/6, Tie2-LacZ and the different subsets of chimeric 
mice were injected i.v. with 1.5107 Bg1-Thy 1.1+ splenocytes in 500 l BSS. 
 
Immunohistology 
Freshly removed organs were immersed in HBSS and snap-frozen in liquid nitrogen. 
Frozen tissue sections were cut in a cryostat and fixed in acetone for 10 minutes. Sections 
were incubated with antibodies against -gal (MP Biomedicals,), CD8 (clone YTS169.4.2) 
followed by goat anti-rat Ig (Caltag Labs) and alkaline phosphatase-labelled donkey anti-goat 
Ig (Jackson ImmunoResearch Labs). Alkaline phosphatase was visualized by using AS-BI 
Results 
- 44 - 
 
phosphate/New Fuchsin, and sections were counterstained with hemalum, and images were 
acquired using a Leica DM R microscope equipped with a Leica DC300 FX camera. Digital 
images were processed using Adobe Photoshop. 
 
Surgical procedure for liver transplantation 
Donor procedure, back-table preparation, and recipient procedure were performed as 
described previously with minor modifications (Tian et al., 2002). Briefly, all vessels and 
ligaments of the liver were dissected in the donor after midline laparotomy. In situ perfusion 
of the liver was performed, using cold (4°C) Ringer's solution. Subsequently, the liver was 
separated from its retroperitoneal attachments and removed. The graft was stored in cold 
(4°C) Ringer's solution for 60 minutes until implantation into the recipient. Following 
hepatectomy of the native liver in the recipient, the donor liver was implanted in an orthotopic 
position. The anhepatic time in the recipient was consistently kept below 20 minutes. The 
portal vein was reconstructed and the liver was reperfused after completing the anastomosis 
between the suprahepatic inferior vena cava of the recipient and donor. Arterial recirculation 
was established by an end-to-side anastomosis between the recipient aorta and an aortic 
segment attached to the hepatic artery of the graft. A single subcutaneous injection of 5 mg 
cefazolin provided antibiotic prophylaxis. 
 
Heterotopic heart transplantation 
Heterotopic vascularized cardiac transplantation was performed according to the method 
described by Corry et al. (Corry et al., 1973). Donor hearts were explanted from either male 
Tie2-LacZ or male C57BL/6 mice. The donor heart was removed from the chest after 
intracaval injection of 1 ml of heparin (100 U/ml), rinsed with NaCl 0.9% and placed on ice. 
After isolation of the recipient's abdominal aorta and inferior vena cava, the donor ascending 
aorta and pulmonary artery were joined end-to-side to the recipient's aorta and vena cava, 
respectively, using 10-0 nylon running suture. The abdomen was closed with individual 
running sutures to musculofascial layer and skins. The recipient mouse was then warmed for a 
few hours during recovery from anesthesia and had free access to water and food. The 
function of the transplanted heart was assessed daily by abdominal palpation. 
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Statistical data analysis 
To evaluate statistically significant differences, the unpaired two-tailed Student's test was 
used. p values smaller than 0.05 were considered statistically significant. Statistical data 
analysis was performed using GraphPad Prism version 4.03 for Windows (GraphPad 
Software Inc., San Diego California USA). 
5.1.4 Results 
5.1.4.1 CD8 T-cell tolerance in Tie2-LacZ mice 
Currently, a number of transgenic mouse lines are available that exhibit EC-restricted 
transgene expression: von Willebrandt Factor-LacZ (Aird et al., 1995) and thrombomodulin-
LacZ (Weiler-Guettler et al., 1996) mice which both show patchy transgene distribution in 
some arteries, and tie2-H-2Kb mice (Limmer et al., 2005) which express the H2-K
b
 molecule 
as a transgene. In this study, Tie2-LacZ mice (Schlaeger et al., 1997) backcrossed to the 
C57BL/6 background have been used because of the uniform -gal Ag expression in EC of all 
organs. It is noteworthy that the intensity of -gal expression in Tie2-LacZ mice is most 
pronounced in small and large arteries, but clearly detectable in venous and capillary EC 
(Figure 5 and Figure S 1). Furthermore, expression levels of -gal mRNA in various organs 
were comparable (Figure S 2) indicating that these mice are well-suited to study EC-CD8
+
  
T-cells interaction in vivo. Indeed, in a previous study, Rothermel et al. (Rothermel et al., 
2004) have used Tie2-LacZ mice on the FVB genetic background to assess CD4
+
 and CD8
+
 
T-cell responsiveness under conditions of persisting Ag expression in EC. Whereas this 
previous investigation suggested that Tie2-LacZ mice can mount CD8
+
 T-cell responses 
against the EC-restricted -gal antigen (Rothermel et al., 2004), the results obtained in the 
present study indicate that CD8
+
 T-cells in Tie2-LacZ mice are tolerant to the -gal antigen. 
This is shown by the fact that Tie2-LacZ mice failed to mount -gal-specific CTL responses 
following infection with -gal-recombinant mouse cytomegalovirus (MCMV-LacZ), whereas 
CD8
+
 T-cell responses against the viral M45 epitope were not influenced by the EC-specific 
transgene expression (Figure 5 B and C).  
We next addressed whether the apparent gal-specific CD8+ T-cell tolerance in Tie2-LacZ 
mice is mediated by thymic negative selection or by peripheral tolerizing mechanisms. To this 
end, Tie2-LacZ mice were crossed with TCR transgenic Bg1 mice which possess CD8
+
  
T-cells that recognize the H2-K
b
-restricted -gal96-103 epitope (Overwijk et al., 1997).  
60 - 70% of the Bg1 CD8
+
 T-cells bind H2-K
b
/-gal96-103 tetramers (Figure 6) and Bg1 CD8
+
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T-cells possess a high functional avidity for the -gal96-103 epitope as shown by target cell 
recognition and proliferation assays (Figure S 4). In the thymus of Tie2-LacZBg1 mice, the 
numbers of transgenic V7 chain-positive and tetramer-binding CD8+ cells were reduced to 
40% (Figure 6), suggesting that central tolerance led to partial deletion of -gal-specific  
T-cells. Interestingly, in peripheral lymphoid organs such as the spleen, the numbers of V7-
positive and -gal96-103 tetramer-binding CD8
+
 T cells was further reduced from 60-70% in 
Bg1 to less than 10% in Tie2-LacZBg1 mice. Thus, at a first glance, it appears that EC-
specific antigen expression in Tie2-LacZ mice precipitated both central and peripheral 
tolerance.  
  Results  
 
- 47 - 
 
 
Figure 5: CD8
+
 T-cell reactivity in Tie2-LacZ mice. (A) Heart and thymus sections of naïve Tie2-LacZ mice 
were stained for -gal and CD8. (B-C) C57BL/6 (B6) and Tie2-LacZ (T2) mice were infected i.v. with 106 pfu 
MCMV-LacZ. (B) Tetramer analysis for the indicated -gal and MCMV-derived M45 epitopes was performed 
on day 6 post infection. Mean percentage of tetramer-positive cells within the CD8 compartment are indicated  
( SEM; n=3-4). (C) Lysis of peptide-pulsed EL-4 cells by MCMV-LacZ-induced CTL. On day 6 post infection, 
splenocytes from the indicated mouse strains were restimulated in vitro for 5 days with -gal497-504, -gal96-103 or 
M45985-993 peptide and tested in a standard chromium release assay. 
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Figure 6: CD8
+
 T-cell tolerance in Tie2-LacZ mice. Tie2-LacZ mice were crossed with TCR trangenic Bg1 
mice. Thymocytes from Tie2-LacZ (T2, upper row), Bg1 (middle row), and Bg1Tie2-LacZ mice (Bg1xT2, 
lower row) were stained for CD4 and CD8 expression. The expression of the transgenic V7 chain and binding 
of the H2-K
b
-gal96-103 tetramer was determined by gating on CD8 T-cells. Values in the upper right quadrant 
indicate mean frequencies of CD4/CD8 positive cells in thymocytes or percentage of antigen-specific cells in 
single CD8 positive thymocytes, respectively (T2, n=2; Bg1; n=3, Bg1T2 n=7). Splenocytes were assessed for 
V7 and CD8 expression. Expression of gal96-103-specific cells was determined by V7 and H2-K
b
-gal96-103 
tetramer staining, gating on CD8 T-cells (T2, n=3; Bg1, n=5; Bg1T2 n=9). 
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5.1.4.2 EC-independent peripheral CD8+ T-cell tolerance 
Peripheral CD8
+
 tolerance can be induced via different cell types including circulating 
hematopoietic cells expressing mhAg (Ehl et al., 1998a; Bonilla et al., 2006), BM-derived 
APC cross-presenting antigen derived from parenchymal tissues (Kurts et al., 1997; Kurts et 
al., 1998), or particular subsets of EC that, as well, possess the ability to cross-present 
circulating antigens (Limmer et al., 2000; Limmer et al., 2005). In order to assess truely EC-
mediated peripheral tolerance induction, we established first a highly sensitive in vivo 
restimulation assay to detect very low amounts of circulating Bg1 cells. To this end, graded 
numbers of sorted CD8
+
Thy1.1
+
 cells from naive Bg1 mice were transferred into  
Thy1.2-positive Tie2-LacZ and C57BL/6 mice. Six days following adoptive transfer, mice 
were infected with MCMV-LacZ and the expansion of Bg1 cells was assessed six days later. 
As shown in Figure 7A, -gal-specific CD8+ T-cells expanded in C57BL/6 but not in  
Tie2-LacZ mice, confirming that Bg1 cells encounter their antigen in Tie2-LacZ mice outside 
of the thymus and that this interaction leads to their deletion. However, reconstituting  
Tie2-LacZ mice with C57BL/6 BM revealed that CD8
+
 T-cell tolerance in Tie2-LacZ mice 
was solely dependent on -gal expression within the BM (Figure 7B and C). These data 
indicate that expression of a mhAg by EC alone is neither sufficient to directly tolerize CD8
+
 
T-cells nor is this antigen available to BM-derived APC in a way that would lead to CD8
+
  
T-cell tolerance. 
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Figure 7: Loss of adoptively transferred Bg1 CD8+ T-cells in Tie2-LacZ mice is not dependent on -gal 
expression by EC. (A) Graded numbers of CD8
+
 Bg1 cells expressing the congenic marker Thy1.1 were 
adoptively transferred into Thy1.2
+
 C57BL/6 or Tie2-LacZ recipient mice. Six days later, mice were challenged 
with 2106 pfu MCMV-LacZ and the proliferation of Bg1 CD8+ T-cells was determined on day six following 
immunization by staining for CD8, Thy 1.1 and the transgenic V7 chain. Representative data from one out of 2 
independent experiments are shown. (B, C) Adoptive transfer of Bg1 CD8
+
 T-cells in bone marrow chimeric 
mice. 5104 (B) or 105 (C) TCR transgenic Thy1.1+ Bg1 cells were adoptively transferred into the indicated 
Thy1.2
+
 bone marrow chimeric mice. Nine days (B) or 30 days (C) later, mice were challenged with 2106 pfu 
MCMV-LacZ and proliferation of Bg1 CD8
+
 T-cells was determined on day six following MCMV-LacZ 
challenge in the indicated organs. Values represent mean percentage ( SEM) of Thy1.1+V7+ cells within the 
CD8 T-cell compartment. 
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5.1.4.3 EC fail to directly activate naive CD8+ T-cells in vivo 
Deletional tolerization of CD8
+
 T-cells via activation-induced cell-death is usually 
associated with a transient period of T-cell activation and proliferation (Ehl et al., 1998b; 
Kyburz et al., 1993). Furthermore, it is possible that EC in Tie2-LacZ mice might directly 
interact with CD8
+
 T-cells in a way that leads to T-cell activation and/or proliferation. In 
order to assess a potential spontaneous T-cell activation by EC in a GVHD-like model 
situation, 3106 CFSE-labelled TCR transgenic CD8+ T-cells were adoptively transferred into 
Tie2-LacZ mice and T-cell activation was monitored as CD44 upregulation on proliferating 
Bg1 cells (Figure 8A). Quantification of gal-dependent T-cell proliferation was achieved by 
adoptive transfer of CSFE-labelled, Thy 1.1-positive CD8
+
 Bg1 cells into either C57BL/6 or 
Tie2-LacZ mice (Figure 8B). This sensitive read-out system was then used to assess whether 
antigen presentation by EC alone is sufficient to mediate CD8
+
 T-cell activation or whether 
bone marrow-derived APC, in particular DC, contribute to the observed initial CD8
+
 T-cell 
triggering.  
An array of BM chimeric mice was generated using different combinations between 
C57BL/6 (B6) and Tie2-LacZ (T2) controls, Tie2-LacZ mice on the C57BL/6
bm1
 background 
(T2bm1) exhibiting a mutated H2-K
b
 molecule that precludes H2-K
b
-restricted presentation, 
and CD11c-DTR mice (Jung et al., 2002) which facilitate the specific ablation of  
CD11c-positive DC in lymphoid organs. As expected, Bg1 cells were not activated in 
B6B6 chimeras (Figure 9A), whereas transgenic CD8+ T cells proliferated in T2T2 
chimeric mice (Figure 9B). Proliferation of Bg1 cells in B6T2 chimeras indicated that BM-
derived non-transgenic APC had activated the transgenic T cells (Figure 9C). This 
interpretation is supported by the fact that Bg1 proliferation was aborted in T2bm1T2 
chimeras where direct and cross-presentation via BM-derived APC is abolished and only EC 
can present the -gal epitope (Figure 9D). Experiments with T2bm1T2bm1 chimeras 
confirmed that Bg1 cells do not proliferate in the absence of the appropriate H2 restriction 
element (Figure 9E). Bg1 activation could be restored in B6T2bm1 chimeras confirming 
that indeed BM-derived APC are crucial in this setting (Figure 9F). Finally, reconstitution of 
T2bm1 mice with BM from CD11c-DTR mice together with diphteria toxin-mediated 
ablation of DC showed that the proliferation of Bg1 cells depended strictly on the cross-
presentation of -gal antigen by DC (Figure 9G). Taken together, these results indicate that 
gal-presenting vascular EC remain immunologically ignored by CD8+ T-cells and that 
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activation and proliferation of CD8
+
 T-cells recognizing the mhAg in Tie2-LacZ mice is 
solely dependent on cross-presentation of Ag by BM-derived DC. 
 
 
 
Figure 8: Activation of Bg1 CD8
+
 T-cells in Tie2-LacZ mice. (A) A total of 1.5107 CFSE-labelled splenocytes 
(corresponding to 3106 CD8+ TCR transgenic T-cells) from Bg1 mice were adoptively transferred into 
C57BL/6 or Tie2-LacZ mice. Mice were sacrificed on day four following transfer and cells from blood, spleen 
and LNs were analyzed by flow cytometry for CFSE dilution and CD44 upregulation on CD8
+
 lymphocytes. 
FACS-plots from one representative out of two independent experiments are shown. (B) Quantification of Bg1 
T-cell proliferation. 1.5107 CFSE-labelled Bg1 Thy1.1+ splenocytes were injected into C57BL/6 or naïve Tie2-
LacZ mice. Mice were killed on day four following transfer and cells from blood, spleen and LNs were analyzed 
by flow cytometry. Values represent mean percentage ( SEM, n=7, pooled data from two independent 
experiments) of proliferating CD8
+
Thy1.1
+
 cells (*, p0.05; **, p0.005; ***, p0.001). 
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Figure 9: In vivo proliferation of Bg1 CD8
+
 T-cells in bone marrow chimeric mice. 1.5107 CFSE-labelled 
splenocytes (corresponding to 3106 CD8+ TCR transgenic T-cells) expressing the congenic marker Thy1.1 were 
adoptively transferred into the indicated Thy1.2
+
 bone marrow chimeras: (A) C57BL/6  C57BL/6,  
(B) Tie2-LacZ  Tie2-LacZ, (C) C57BL/6  Tie2-LacZ, (D) Tie2-LacZB6.C-H2bm1  Tie2-LacZ,  
(E) Tie2-LacZB6.C-H2bm1  Tie2-LacZB6.C-H2bm1, (F) C57BL/6  Tie2-LacZB6.C-H2bm1, and (G) 
CD11cDTR  Tie2-LacZB6.C-H2bm1. CD11c-DTR bone marrow recipients had been injected 
intraperitoneally with 4 ng/g body weight diphteria toxin which led to a 95 to 98 % depletion of CD11c
+
 cells for 
> 48 h. Mice were sacrificed on day four following adoptive transfer and cells from blood, and spleens were 
analyzed by flow cytometry. Values in the histograms represent mean percentage ( SEM, n=5-7, pooled data 
from three independent experiments) of proliferating CD8
+
Thy1.1
+
 T-cells.  
 
5.1.4.4 Immunologic ignorance of antigen expressing EC in vascularized organ transplants 
In order to assess whether the above findings, obtained in a GVHD-like setting, also reflect 
EC-CTL interaction within vascularized organ grafts, a series of heart and liver 
transplantations were performed. Heterotopically transplanted Tie2-LacZ hearts were well-
accepted in C57BL/6 recipients and spontaneous CD8
+
 T-cells responses against both the  
-gal497-503 (Figure 10A) and the -gal96-103 epitope (not shown) could not be detected. To 
analyze with higher sensitivity the effect of -gal expression on vascular EC, we employed 
the adoptive transfer system of CSFE-labelled Bg1 cells. Two weeks following heterotopic 
heart transplantation (Figure 10B and D) or orthotopic liver transplantation (Figure 10C and 
E), CFSE-labelled Bg1 CD8
+
 T cells were adoptively transferred either into recipients that 
had received C57BL/6 (Figure 10B and C) or transgenic Tie2-LacZ organs (Figure 10D and 
E). This analysis revealed no significant differences in Bg1 CD8
+
 T-cell activation between 
recipients of Tie2-LacZ and C57BL/6 control organs indicating that EC within the 
transplanted organs had not primed naive CD8
+
 T-cells. 
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Figure 10: Lack of CD8+ cell activation in naive recipients of Tie2-LacZ vascularized organ grafts. (A) 
Spontaneous -gal-specific CD8+ T-cell reactivity measured by tetramer analysis. C57BL/6 recipients received 
either C57BL/6 (B6  B6) or Tie2-LacZ (T2  B6) hearts and the presence of -gal497-504-specific CD8
+
  
T-cells in blood was assessed by flow cytometry on day 20 post transplantation. (B-E) Activation of CD8
+
 Bg1 
T-cells after adoptive transfer of 1.5107 CFSE-labelled Bg1 splenocytes in C57BL/6 recipients on day 10 post 
transplantation. (B, D) Heterotopic heart transplantation with donor organs from C57BL/6 (n=7) (B) and Tie2-
LacZ (n=8) (D) mice. Orthotopic liver transplantation with donor organs from C57BL/6 (n=5) (B) and Tie2-
LacZ (n=4) (D) mice. Mice were sacrificed on day four following adoptive transfer and cells from blood were 
analyzed by flow cytometry. Values in the histograms represent mean percentage ( SEM) of proliferating 
CD8
+
Thy1.1
+
 cells. 
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5.1.5 Discussion 
In this study, we have used antigen-transgenic mice with uniform mhAg expression in EC 
in combination with CD8
+
 T-cell TCR transgenics to demonstrate that mhAg presentation by 
EC does neither precipitate T-cell activation nor tolerization. The lack of any tolerizing effect 
of prolonged EC-CD8
+
 T-cell interaction is unexpected because non-activated, mhAg 
presenting EC in Tie2-LacZ provide "signal 1", i.e. antigen, in the absence of "signal 2", i.e. 
costimulation. Thus, the EC-associated antigen in Tie-LacZ mice that is expressed in a wide-
spread and easily accessible fashion should lead to CD8
+
 T-cell tolerance, in particular, in the 
absence of "danger signals" (Matzinger, 1994). One could argue that EC possess an impaired 
capacity to present immunodominant peptides (Kummer et al., 2005) and therefore fail to 
interact with CD8
+
 T-cells. In Tie2-LacZ mice, however, EC can become target cells of CTL 
that have been appropriately activated via DC priming in vivo thereby leading to typical 
vascular rejection of organ grafts (Engeler et al., manuscript in preparation). Furthermore, it is 
unlikely that the antigen expression levels in EC of Tie2-LacZ are too low to allow for 
productive EC-CD8
+
 T-cell interaction because sufficient EC-associated antigen is present in 
Tie2-LacZ mice for indirect (cross-) presentation by BM-derived DC. It is therefore possible 
that studies describing activation and subsequent tolerization of CD8
+
 T-cells, for example by 
particular subsets of EC such as liver sinusoidal EC (Limmer et al., 2000; Limmer et al., 
2005; Berg et al., 2006) may not have considered the contribution of professional APC such 
as DC and other BM-derived APC. 
Indeed, the complexity of the multi-cellular processes involved in EC-mediated antigen 
presentation in vivo requires careful consideration of possible confounding factors. Rothermel 
et al. (Rothermel et al., 2004) have suggested that immune recognition of EC is context-
dependent with antigen expressed in hearts of Tie2-LacZ mice being immunologically 
ignored whereas EC presenting -gal antigen in skin are immunogenic and thus elicit T-cell 
responses capable of rejecting skin grafts. The results of our study clearly confirm the notion 
that direct presentation of mhAg by EC is accompanied by immunologic ignorance. However, 
in the context of mhAg presentation in transplant vasculopathy and GVHD, DC are probably 
the most important cell population that cross-presents the antigen in an immunogenic fashion.  
Our study revealed further details that could confound the analysis of T-cell 
activation/tolerization in Tie2-LacZ mice: gal-specific CD8+ T-cells were effectively 
tolerized in non-irradiated Tie2-LacZ and in T2T2 bone marrow chimeric mice. We 
conclude from these findings that cells within the bone marrow, but not professional APC that 
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descend from bone marrow precursors exert a tolerizing stimulus in Tie2-LacZ mice. 
Hematopoietic stem cells express the angiopoetin 1 receptor Tie2 (Arai et al., 2004) and it is 
therefore likely that the complete tie2-promoter that has been used in Tie2-LacZ (Schlaeger et 
al., 1997) is active in hematopoietic cells. Since circulating lymphocytes presenting mhAg 
efficiently tolerize naive CD8
+
 T-cells (Ehl et al., 1998b; Bonilla et al., 2006), it is reasonable 
to assume that naive CD8
+
 T-cells travelling through the BM can receive tolerizing stimuli 
within this compartment. Using Tie2-LacZ BM chimeras, it will be feasible to further 
characterize those cells within the bone marrow that are highly efficient in inducing tolerance 
to mhAg.  
Taken together, this study identifies the initial priming of mhAg-specific CD8
+
 T-cells via 
DC as a critical step in the generation of alloimmune responses. Therefore, it appears to be 
crucial that therapeutic intervention should aim at preventing or at least reducing the initial  
T-cell activation against mhAg. Indeed, blockade of essential costimulatory pathways such as 
CD40-CD40L (Larsen et al., 1996; Ford et al., 2007) or CD28-CD80/86 (Salomon and 
Bluestone, 2001) interaction during initial DC-mediated CD8
+
 T-cell stimulation bear a high 
potential for clinical application. It may well be that a combination of costimulatory blockade 
before and during priming of EC-specific CD8
+
 cell responses together with the induction of 
regulatory T-cells (Salomon and Bluestone, 2001) will help to protect EC from injury 
following transplantation of vascularized organs or during GVHD. 
5.1.6 Supplemtary data 
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Figure S 1: gal and CD8 staining of salivary gland, spleen and liver sections of naïve Tie2-LacZ mice. Freshly 
removed organs were immersed in HBSS and snap-frozen in liquid nitrogen. Frozen tissue sections were cut in a 
cryostat and fixed in acetone for 10 min. Sections were incubated with antibodies against gal (MP 
Biomedicals,), CD8 (clone YTS169.4.2) followed by goat anti-rat Ig (Caltag Labs) and alkaline phosphatase-
labelled donkey anti-goat Ig (Jackson ImmunoResearch Labs). Alkaline phosphatase was visualized by using 
AS-BI phosphate / New Fuchsin, and sections were counterstained with hemalum, and pictures were acquired 
using a Leica DM R microscope. 
 
 
 
 
 
Figure S 2: LacZ mRNA copy numbers in liver, spleen, heart, kidney, thymus and BM of naïve Tie2-LacZ 
mice. Organs were homogenized in Trizol (Sigma) using a MagNA Lyser instrument (Roche Diagnostics). RNA 
was isolated by isopropanol percipitation, washed with ethanol 70% and resuspended in DEPC-water. RNA (10 
g) was subjected to RT-PCR analysis. For RT-PCR the high capacity cDNA archive Kit from Applied 
Biosystem (ABI PRISM, Warrington, United Kingdom) was used according to the specifications of the 
manufacturer to generate cDNA from RNA samples. Quantitative real-time PCR was performed using a 
LightCycler (Roche Diagnostics) and the LightCycler FastStart DNA Master
PLUS
 HybProbe reaction mix (Roche 
Diagnostics) following the manufacturer's protocol. Data analysis was performed with LightCycler Software 3 
(Roche Diagnostics). Oligonucleotides were purchased from Microsynth (Balgach, Switzerland). The following 
oligonucleotides from LacZ sequences were used as primers for quantitative real-time PCR: 5'-
GCGTGGATGAAGACCAGC-3' and 5'-CGAAGCCGCCCTGTAAAC-3'. The following oligonucleotides were 
used as probes: 5' CAGTCTTGGCGGTTTCGCTAA 3' (probe 1) and 5' TACTGGCAGGCGTTTCGTCAG 3' 
(probe 2). Probe 1 carried a 3' FAM reporter and probe 2 was Cy5 labelled at the 5' end. Thermal cycling started 
with HotStarTaq activation during 15 min at 95°C. Thereafter 50 cycles of amplification were run consisting of 
15 s at 95°C, 20 s 60°C and 20 s of 72°C. A negative control, containing reagents only, and serial dilutions of 
plasmid containing the specific LacZ sequence were included in each run to generate a standard curve. The 
concentrations of the plasmid dilutions were: 280000, 28000, 2800, 280 and 28 copies per reaction. LacZ mRNA 
concentration in the unknown samples was calculated by the ABI Prism Software using the data from the 
standard curve. Each sample was measured twice and the average concentration was used. Final copy numbers 
were calculated per g total RNA. 
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Figure S 3: Expression of LacZ transcripts in sorted bone marrow cells. For cell sorting, the FACS Aria (BD 
Biosciences) was used. Erythrocyte-depleted BM cells were stained in IMDM 2% FBS with saturating 
concentrations of anti-TCR, anti-CD3, anti-CD11b, anti-CD11c, anti-CD19, anti-CD117, and anti-Ly6A/E 
(SCA-1). Following a 30 min incubation at 4°C, cells were washed in PBS 2% FBS and resuspended in PBS, 
filtered through a 20 µm diameter nylon mesh, and resuspended at about 20×10
6
/mL in filtered PBS 2% FBS 
prior to sorting. Reanalysis of sorted cells indicated purity >95%. Real-time RT-PCR for the quantification of 
LacZ expression in the sorted BM cells was performed essentially as described in Figure S2 with the following 
modifications. Expression of the TATA-binding protein (TBP) was used for normalization. The following 
primers were used for amplification of TBP: TBPfw CCTTCACCAATGACTCCTATGAC, TBPrev 
CAAGTTTACAGCCAAGATTCAC. Amplification program for the LightCycler RT-PCR was 95°C 15 min; 50 
cycles – 95°C 10 sec, 58°C 10 sec, 72°C 20 sec. The level of expression between samples derived from the 
different cell populations was calculated by the comparative CT method (CT) with expression in total bone 
marrow cells set as reference. 
 
 
Figure S 4: Functional avidity of TCR transgenic Bg1 CD8
+
 T-cells. (A) EL-4 cells pulsed with different 
concentration of the gal96-103 (DAPIYTNV) peptide or without peptide (negative control) were used as target 
cells in a standard 
51
Cr release assay. Cells were labelled with 200 Ci 51Cr (EGT Chemie, Tägerig, Switzerland) 
for 1 h at 37°C. A total of 10
4
 target cells/well were incubated for 5h in 96-well round bottom plates with 3-fold 
serial dilutions of effector cells. CTL from naïve Bg1 mice that were restimulated with gal96-103 (DAPIYTNV) 
for three days and were tested at a effector:target ratio of 10:1. (B) MACS-purified CD8
+
 splenocytes from Bg1 
mice were cocultured with gal96-103 (DAPIYTNV) peptide presenting DC. DC were generated from bone 
marrow of C57BL/6 mice using GM-CSF containing medium as described previously (Ludewig et al., 1998, J. 
Virol. 72:3812). DC were pulsed at the indicated concentration of the gal96-103 (DAPIYTNV) peptide or left 
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unloaded as a negative control and plated onto a 96-well plate in RPMI 1640 (Sigma) supplemented with 5% 
FCS, 25mM L-glutamine, and 100U/ml penicillin with 100g streptomycin sulfate. Responder to stimulator ratio 
of the displayed data was 30:1. Cells were incubated at 37°C for 60 hours. During the last 12 hours of coculture, 
1 Ci of 3H thymidine (MP Biomedical, EGT Chemie, Tägerig, Switzerland) was added to each well. To 
measure incorporation into DNA, the plates were frozen, thawed, harvested, and counted on a beta liquid 
scintillation counter (TRI-CARB, Packard). The mean of triplicates ( SD) was calculated, background values 
from cultures with unpulsed DC were subtracted.  
 
 
Figure S 5: Phenotype of MCMV-LacZ-activated Bg1 TCR transgenic T cells in B6B6 and B6T2 chimeras. 
The indicated bone marrow chimeric mice received 10
5
 CD8
+
Thy1.1
+
 cells from naive Bg1 mice. Nine days 
following adoptive transfer, mice were infected with MCMV-LacZ and the phenotype of the activated Bg1 cells 
was assessed six days later. Bg1 T cells activation was measured as upregulation of CD44 (A), and down-
regulation of CD62L (B). Progression of activation-induced cell death was measured as Annexin V upregulation 
(C). Expression of the respective markers on naïve CD8
+
 T-cells from B6 mice is shown as controls. Mean 
fluorescence intensity is indicated (n=2-3).  
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Figure S 6: Fate of Bg1 TCR transgenic T cells in T2T2 chimeric mice. 1.5107 CFSE-labelled splenocytes 
(corresponding to 3106 CD8+ TCR transgenic T cells) from Bg1 mice were adoptively transferred into T2T2 
bone marrow chimeras. Mice were sacrificed on days 4 and 8 following transfer and dividing Bg1 cells from 
spleens were analyzed by flow cytometry for CD44 (A), and Annexin V (B) upregulation. Total numbers of 
transgenic Bg1 cells in spleens of recipient T2T2 and B6B6 mice were determined (C) at the indicated time 
points. 
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5.2.1 Abstract  
Background: Occlusive coronary artery disease is the major cause for cardiac allograft 
rejection. Endothelial cells (EC) are the first graft cells encountered by host lymphocytes and 
are therefore primary targets of activated cytotoxic T-lymphocytes (CTL). This study 
determined whether CTL-mediated injury of EC exclusively presenting a minor 
histocompatibility antigen (mhAg) would suffice to precipitate transplant vasculopathy (TV). 
Methods: The interaction of CTL with antigen-presenting EC in vivo has been examined 
here using a transgenic mouse model with beta-galactosidase (-gal) expression confined to 
the vascular endothelium (Tie2-LacZ mice). Cardiac grafts from Tie2-LacZ mice were 
transplanted heterotopically into C57BL/6 recipients. EC-specific CTL were activated in vivo 
either by priming with -gal peptide-pulsed dendritic cells (DCs) or by infection with -gal-
recombinant mouse cytomegalovirus (MCMV-LacZ).  
Results: In the absence of -gal-specific effector CTL, Tie2-LacZ heart grafts remained 
immunologically ignored for more than 100 days post transplantation. Repetitive priming 
with -gal peptide-pulsed DC elicited severe vascular inflammation in transplanted Tie2-
LacZ hearts with neointima formation and vascular occlusion. Activation of EC-specific CTL 
by infection with MCMV-LacZ caused less severe vascular inflammation in Tie2-LacZ hearts 
presumably due to the timely limited activation of -gal-specific CTL under these conditions. 
Conclusions: EC injury mediated by activated CTL recognizing a mhAg specifically 
expressed on EC is sufficient to elicit TV. Prolonged antigen presentation within secondary 
lymphoid organs - most likely by DCs - appears to be a key factor for the development of 
chronic vascular rejection. 
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5.2.2 Introduction 
Despite advances in immunosuppressive therapies for acute allograft rejection, successful 
long-term outcome of transplanted solid organs is still hampered by late graft failure (Keck et 
al., 1999; Cecka, 1999). Chronic graft rejection is caused, in large part, by host-anti-graft 
immune responses that target cells of the graft vasculature thereby precipitating transplant 
vasculopathy (TV) (Libby and Pober, 2001). The most prominent feature of TV is the 
remodelling of graft vessels caused by neointima formation and progressive luminal 
narrowing (Mitchell and Libby, 2007). Since the progressive TV-associated loss of lumen 
affects mainly conduit arteries, this disease entity can also be referred to as "graft 
arteriosclerosis" (Tellides and Pober, 2007). Endothelial cells (EC) are the first graft cells 
encountered by the host immune system and it is thus most likely that a complex series of 
immune-mediated EC injuries initiate and drive the process of chronic vascular rejection 
(Valantine, 2003). It is therefore important to delineate the specifics of the inciting EC injury 
in well-defined model systems. 
Among the different immune effector molecules that have been implicated in the 
pathogenesis of TV, IFN- appears to be a particularly important factor. This is supported not 
only by the fact that IFN- transcription in endomyocardial biopsies of human heart grafts is 
upregulated prior the development of TV (Russell et al., 1994a), but also by several 
experimental studies showing that IFN- is instrumental for the development of TV (Russell 
et al., 1994d; Nagano et al., 1997). Studies of Russell and colleagues indicated that cardiac 
TV in a MHC-disparate setting is largely driven by T-cells (Russell et al., 1994b) and that 
humoral alloresponses can contribute to the chronic inflammatory process (Russell et al., 
1994c; Russell et al., 1997). It is important to note that these and other experimental studies 
on cardiac TV (Armstrong et al., 1997a; Armstrong et al., 1997b) had to employ 
immunosuppressive treatment to down-modulate a full-blown alloimmune response. 
Evidently, such a setting precludes comprehensive functional analyses of T-cells involved in 
the disease process.  
A major aim of the present study was to develop an experimental system that facilitates in 
vivo studies on the cognate interaction of EC with activated CTL in a heterotopic heart 
transplantation model. To this end, we employed a transgenic mouse with EC-specific  
-galactosidase (-gal) expression under the control of the Tie2 promoter (Tie2-LacZ mice) 
(Schlaeger et al., 1997). These mice had been generated on the FVB/NJ background (H2q 
haplotype) thus hampering thorough immunological analysis of EC-CTL interaction 
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(Rothermel et al., 2004). Following backcrossing to the C57BL/6 background, we have shown 
in a recent study (Bolinger et al., 2008) that -gal expression by EC in heterotopically 
transplanted Tie2-LacZ hearts or orthotopically transplanted Tie2-LacZ livers did not result in 
activation of naive CD8
+
 T-cells. Furthermore, generation of bone marrow (BM) chimeric 
mice that facilitated selective ablation of CD11c-positive dendritic cells (DC) revealed that 
EC-associated minor histocompatibility antigen (mhAg) has to be cross-presented by DC in 
order to elicit CD8
+
 T-cell activation. Having thus established that naive CTL 
immunologically ignore vascular EC expressing a mhAg, we examined in the present study 
whether -gal-specific effector CTL are able to mediate significant EC injury and whether 
this particular interaction would suffice to precipitate TV in transplanted Tie2-LacZ hearts. 
We found that priming with -gal peptide-pulsed DC induced vascular inflammatory disease 
with neointima formation and vascular occlusion. Less pronounced activation of EC-specific 
CTL by infection with -gal-recombinant mouse cytomegalovirus (MCMV-LacZ) led to 
reduced vascular inflammation in Tie2-LacZ hearts suggesting that it is the DC-mediated, 
prolonged presentation of mhAg within secondary lymphoid organs that drives activation of 
EC-specific CTL fostering thereby the development of chronic vascular rejection. 
5.2.3 Materials and Methods 
Mice 
Male and female C57BL/6 mice were obtained from Charles River (Sulzfeld, Germany). 
Tie2-LacZ mice (Schlaeger et al., 1997) had been crossed to the C57BL/6 background for at 
least 14 times. The presence of the -gal transgene was determined by PCR from genomic 
DNA. Mice were thymectomized at 6-7 weeks of age as described (Aichele et al., 1995) and 
used 4 weeks after thymectomy. All animals were kept under conventional conditions in 
individually ventilated cages and fed with normal chow diet. Experiments were carried out 
with age (6-10 weeks) and sex-matched animals. Experiments were performed in accordance 
with Swiss Cantonal and Federal legislations. 
 
Viruses and peptides 
Recombinant MCMV expressing the -gal protein under the transcriptional control of the 
human CMV ie1/ie2 promoter-enhancer (MCMV-LacZ RM427 (Manning and Mocarski, 
1988)) was kindly provided by Prof. E. S. Mocarski (Stanford University, San Francisco). 
MCMV-LacZ was propagated and titrated on NIH 3T3 cells (ECACC, UK) and injected 
Results 
- 66 - 
 
intravenously at a dose of 2106 pfu. -gal96-103 (DAPIYTNV) (Overwijk et al., 1997),  
-gal497–504 (ICPMYARV) (Oukka et al., 1996) and MCMV M45985-993 (HGIRNASFI) (Gold 
et al., 2002) peptides were purchased from Neosystem (Strasbourg, France). 
 
Antibodies and flow cytometry 
Anti-CD8-FITC and anti-IFNγ-PE were obtained from BD PharMingen (Basel, 
Switzerland). For flow cytometry, single cell suspensions were generated from the indicated 
organs, and 1×10
6
 
cells were incubated with the indicated mAb at 4°C for 20 min. For PBL 
samples, erythrocytes were lysed with FACS Lysing Solution (BD PharMingen). Cells were 
analyzed with a FACScalibur flow cytometer using the CellQuest software (BD Biosciences). 
Cells were analyzed by flow cytometry, gating on viable leukocytes using  
7-aminoactinomycin D (Sigma). 
 
Construction of tetrameric MHC class I-peptide complexes and flow cytometry 
MHC class I monomers complexed with -gal (H-2Kb) or M45 peptides (H-2Db) were 
produced as previously described (Altman et al., 1996) and tetramerized by addition of 
streptavidin-PE (Molecular Probes, Eugene, OR). At the indicated time points following 
infection, organs were removed and single cell suspensions were prepared. Aliquots of 5106 
cells or 300 l of blood were stained using 50 l of a solution containing tetrameric  
class I-peptide complexes at 37°C for 10 minutes followed by staining with anti-CD8-FITC 
(BD Pharmingen) at 4°C for 20 min. Absolute cell counts were determined by counting 
leukocytes in an improved Neubauer chamber. 
 
DC preparation and injection 
DC were generated from C57BL/6 bone marrow as described previously (Ludewig et al., 
1998a). Before injection, cells were loaded with the gal497–504 peptide for 1 h at 37°C, 
washed three times with ice-cold BSS and resuspended in BSS at a concentration of 4105 
DC/ml. DC were injected in 500 l BSS i.v. on days 0, 2, 10, and 12.  
 
Immunohistology 
Freshly removed organs were immersed in HBSS and snap-frozen in liquid nitrogen. 
Frozen tissue sections were cut in a cryostat and fixed in acetone for 10 minutes. Sections 
were incubated with antibodies against -gal (MP Biomedicals,), CD8 (clone YTS169.4.2), or 
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F4/80 (Biomedicals AG, clone BM8) followed by goat anti-rat Ig (Caltag Labs) and alkaline 
phosphatase-labelled donkey anti-goat Ig (Jackson ImmunoResearch Labs). Alkaline 
phosphatase was visualized by using AS-BI phosphate/New Fuchsin, and sections were 
counterstained with hemalum. Hematoxylin-eosin, and elastica-Van Giesson (EVG) stainings 
were done following standard procedures. Images were acquired using a Leica DM R 
microscope equipped with a Leica DC300 FX camera. Digital images were processed using 
Adobe Photoshop. 
 
Heterotopic heart transplantation 
Heterotopic vascularised cardiac transplantation was performed according to the method 
described by Corry et al. (Corry et al., 1973). Donor hearts were explanted from either male 
Tie2-LacZ or male C57BL/6 mice. The donor heart was removed from the chest after 
intracaval injection of 1 ml of heparin (100 U/ml), rinsed with NaCl 0.9% and placed on ice. 
After isolation of the recipient's abdominal aorta and inferior vena cava, the donor ascending 
aorta and pulmonary artery were joined end-to-side to the recipient's aorta and vena cava, 
respectively, using 10-0 nylon running suture. The abdomen was closed with individual 
running sutures to musculo-fascial layer and skin. The recipient mouse was then warmed for a 
few hours during recovery from anaesthesia and had free access to water and food. The 
function of the transplanted heart was assessed daily by abdominal palpation. 
 
Histological scoring of chronic vascular transplant rejection 
Based on histological changes observed in chronic allograft rejection, we established a 
modified scoring system to analyze different degrees of vascular transplant rejection based on 
criteria previously published (Hirozane et al., 1995; Russell et al., 1994d) using a scale from 0 
to 3 for the different pathological alterations. The degrees for intimal thickening of coronary 
arteries (0 = <10%; 1 = 10 to <50%; 2 = 50 to <90%; 3 = 90-100% luminal occlusion in at 
least one artery/section), perivascular fibrosis (0 = no changes; 1 = minor fibrotic changes 
around 1 to 3 arteries/section; 2 = vast fibrotic changes around 1 to 3 arteries/section; 3 = vast 
fibrotic changes around more than 3 arteries/section), and perivascular and vascular 
inflammatory infiltrates (0 = no inflammatory infiltrates; 1 = few inflammatory infiltrates 
around 1 to 3 arteries/section; 2 = vast inflammatory infiltrations around 1 to 3 
arteries/section; 3 = vast inflammatory infiltrates in more than 3 arteries/section) were 
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determined. Six to eight sections from each heart were evaluated by two independent 
observers blinded for the tested specimen. 
 
Statistical data analysis 
To evaluate statistically significant differences, the unpaired two-tailed Student's test or the 
nonparametric Kruskal-Wallis test were used. p values smaller than 0.05 were considered 
statistically significant. Statistical data analysis was performed using GraphPad Prism version 
4.03 for Windows (GraphPad Software Inc., San Diego California USA). 
5.2.4 Results 
5.2.4.1 -gal-specific immune responsiveness in heart transplant recipients 
We have shown previously that EC-associated mhAg in Tie2-LacZ hearts transplanted into 
naive C57BL/6 recipients remains immunologically ignored during the first 2-3 weeks post 
transplantation (Bolinger et al., 2008). To determine whether EC in transplanted Tie2-LacZ 
hearts remain intact over a longer period of time, we performed two independent series of 
transplantations of Tie2-LacZ (T2B6, n=5) or C57BL/6 (B6B6, n=6) hearts in C57BL/6 
recipients. Daily palpation revealed that Tie2-LacZ hearts were well-accepted even over a 
period of 100 days. In situ analysis on day 100 post transplantation showed that inflammatory 
reactions both in T2B6 and B6B6 hearts were transplantation procedure-associated with 
thrombus organization in the left ventricle. Importantly, hearts from both groups lacked signs 
of vascular rejection (Figure 11). Furthermore, -gal-expression in coronary arteries of 
T2B6 heart was preserved (Figure 11B, lower right panel) indicating that the graft 
endothelium of Tie2-LacZ had not been replaced by recipient EC.  
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Figure 11: In situ analysis of heterotopically transplanted (A) C57BL/6 (B6B6) and (B) Tie2-LacZ (T2B6) 
hearts on day 100 post transplantation. Hematoxylin-eosin (HE), -CD8, -CD4, and -F4/80 stainings are 
indicated. Original magnification: ×200 (HE overview: ×16). 
 
Next, we assessed whether the persistent presence of a mhAg in the vasculature of a heart 
graft affected CTL reactivity. To this end, C57BL/6 recipients of transgenic and control hearts 
were challenged with -gal peptide-pulsed DC. In this setting, three different scenarios can be 
envisioned: (i) elevated CTL reactivity in T2B6 recipients due to preactivation of CTL, (ii) 
no or lowered CTL reactivity as a consequence of tolerizing stimuli, and (iii) no alteration in 
CTL reactivity because of immunologic ignorance. DC-immunization elicited a comparable 
expansion of -gal-specific CD8+ T-cells both in recipients of Tie2-LacZ and C57BL/6 
control hearts (Figure 12A and B) supporting the notion that mhAg presentation by cardiac 
EC did neither activate nor tolerize naive CTL. To further substantiate this finding and to 
exclude that recent thymic emigrants had replenished a pool of -gal-reactive CTL that were 
tolerized due to a low-level exposure to their cognate antigen in recipients of Tie2-LacZ 
hearts, transgenic hearts were transplanted into mice that had been thymectomized 4 weeks 
before heart transplantation. As shown in Figure 12C, induction of -gal-specific CTL in 
thymectomized recipients of Tie2-LacZ hearts was not affected by the replenishment of the 
peripheral T-cell pool from the thymus. Taken together, these data provide further evidence 
that a mhAg antigen expressed by vascular EC remains immunologically ignored.  
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Figure 12: CTL reactivity in recipients of C57BL/6 (B6B6) or Tie2-LacZ (T2B6) heart transplants 
following DC immunization. (A, B) Four weeks post transplantation; mice were repetitively immunized with 
2×10
5
 gal peptide-pulsed DC. (A) Representative FACS histograms from blood of B6B6 and T2B6 mice 
on day 7, or untreated B6 recipients of a Tie2-LacZ heart on day 30 post transplantation. Values in the upper 
right quadrant represent percentage of tetramer-positive CD8
+
 T-cells. (B) Percentage of gal497-504–specific 
CD8
+
 T-cells in blood on day 7 post immunization (left panel), and in spleens on day 15 post immunization 
(right panel) (mean SEM; n=4-7 animals per group). (C) CD8+ T cell responses in thymectomized mice 
following DC immunization. Male C57BL/6 mice were thymectomized, and received two weeks following 
thymectomy either C57BL/6 or Tie2-LacZ hearts. Four weeks post transplantation, mice were immunized with 
DC as in (A and B). Percentage of gal497-504–specific CD8
+
 T-cells in blood (left panel), and in spleens on day 
15 post immunization (right panel) (mean SEM; n=3 animals per group) Statistical analysis using the 
nonparametric Kruskal-Wallis test indicated no significant difference between the different groups (p>0.05 for B 
and C). 
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5.2.4.2 CTL-induced vascular rejection after DC immunization 
In the next set of experiments, we assessed whether EC in transplanted Tie2-LacZ hearts 
may serve as target cells for activated CTL. Recipient mice were challenged with -gal497–504 
peptide-loaded DC starting 4 weeks post transplantation. Two injections of -gal peptide-
pulsed DC (days 0 and 2), were sufficient to generate significant CTL responses on day 7 
(Figure 12) and to precipitate significant inflammatory reactions around coronary arteries of 
T2B6 hearts, whereas the vasculature of B6B6 hearts did not show signs of inflammation 
(Figure 13A). Based on our previous experience with DC-based immunization against 
tumours (Ochsenbein et al., 1999; Ludewig et al., 2004) and the requirement of prolonged 
DC-mediated antigen presentation to precipitate autoimmune disease (Ludewig et al., 1998b; 
Ludewig et al., 2001), immunization of transplant recipients was repeated on days 10 and 12, 
and hearts were evaluated for signs of vascular rejection on day 15 following the first DC 
application. Histological analysis revealed typical signs of chronic vascular rejection 
including intimal thickening combined with perivascular infiltrations of CD8
+
 T cells and 
F4/80-positive macrophages, perivascular fibrosis, and vascular occlusion (Figure 13B). Since 
these pathological alterations were prominent in T2B6 hearts, we developed a scoring 
system based on criteria published by Russell et al. (Russell et al., 1994d) and by Hirozane et 
al. (Hirozane et al., 1995). T2B6 hearts from DC-immunized recipients showed 
significantly more perivascular infiltration (Figure 14A), intimal thickening (Figure 14B), and 
perivascular fibrosis (Figure 14C) compared to B6B6 hearts. The overall vascular score of 
T2B6 hearts (Figure 14D) clearly indicates that this read-out is well-suited to monitor the 
vigour of vascular rejection in this setting.  
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Figure 13: In situ analysis of transplanted Tie2-LacZ hearts following repetitive DC immunization on days 7 
(A) and 15 (B) post immunization. Hematoxylin-eosin (HE), elastic-van Giesson (EVG), -CD8, -CD4, and  
-F4/80 stainings are indicated. Original magnification: ×200. 
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Figure 14: Quantification of vascular rejection following DC immunization. (A) Perivascular infiltration, (B) 
intimal thickening, (C) perivascular fibrosis, was determined on heart sections on day 15 post DC immunization. 
(D) Total of the vascular rejection indices. Values represent scores of individual mice, horizontal bars represent 
mean values. 
 
5.2.4.3 Virus-induced vascular pathology in transplanted Tie2-LacZ hearts 
Epidemiologic and experimental data indicate that human cytomegalovirus (HCMV) 
represents an important viral pathogen that elicits arterial inflammation and may thereby 
exacerbate TV (Valantine, 2004; Potena and Valantine, 2007). It has been suggested that 
CMV can alter the susceptibility of EC to CTL-inflicted injury by fostering upregulation of 
adhesion and MHC molecules (Sedmak et al., 1994; van Dorp et al., 1989) thereby rendering 
infected EC better targets for antiviral CTL. To assess the impact of murine CMV (MCMV) 
infection on chronic vascular rejection in the Tie2-LacZ heart transplant setting, we infected 
B6B6 and T2B6 recipients with -gal-recombinant MCMV (MCMV-LacZ). Peak 
expansion of -gal-specific CTL on day 6 post infection (Figure 15A, left panel), was lower 
compared to DC-based immunization (Figure 12). Furthermore, MCMV-induced CTL 
responses showed a pronounced contraction to less than 0.5% -gal-specific CTL in the CD8+ 
T-cell compartment on day 14 post infection (Figure 15, right panel). Immunhistologic 
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analysis of heart sections on day 14 following MCMV-LacZ infection revealed a significantly 
higher amount of perivascular inflammatory infiltrates (Figure 15B and C, left panel) in 
T2B6 compared to B6B6 hearts. These infiltrates were mainly CD8+ T-cells (Figure 15B, 
right panel). Interestingly, intimal thickening and perivascular fibrosis were not detectable 
(Figure 15B and C) indicating that the MCMV-LacZ-driven CTL response was sufficient to 
direct activated CTLs to antigen-expressing blood vessels, but that this activation did not 
suffice to generate the full pathology of vascular rejection. 
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Figure 15: Immune reactivity and vascular pathology following MCMV-LacZ infection. C57BL/6 recipients of 
Tie2-LacZ (T2B6) or C57BL/6 (B6B6) hearts were infected with 2x106 pfu MCMV-LacZ 4 weeks after 
transplantation. (A) CTL activation in blood and spleens was determined by tetramer analysis for the indicated 
-gal and MCMV-derived M45 epitopes on days 6 and 14, respectively. Mean percentage of tetramer-positive 
cells within the CD8 compartment are indicated ( SEM; n=3-4). (B) In situ analysis of heterotopically 
transplanted C57BL/6 (B6B6) and Tie2-LacZ (T2B6) hearts on day 14 post infection. Hematoxylin-eosin 
(HE), elastic-van Giesson (EVG), and -CD8 stainings are shown. Original magnification: ×200. (C) 
Quantification of vascular rejection following MCMV-LacZ infection measured as perivascular infiltration, 
intimal thickening, and perivascular fibrosis on day 14 post MCMV-LacZ infection. Values represent scores of 
individual mice, horizontal bars represent mean values.  
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5.2.5 Discussion 
It has been suggested that TV underlying chronic graft failure represents a delayed-type 
hypersensitivity response directed against cells of the vascular wall (Libby et al., 1989). The 
present study further supports this notion by providing a mechanistic link between direct T-
cell-mediated EC injury and subsequent pathological remodelling of coronary arteries. In a 
model situation where activated CTL recognizing an EC-specific mhAg cause vascular 
inflammation, prolonged antigen presentation by DC within secondary lymphoid organs was 
necessary and sufficient for the development of chronic vascular rejection. 
Within vascularised organ transplants, donor EC can persist and may therefore contribute 
to chronic alloimmune stimulation. Under particular circumstances, EC may even initiate 
CTL responses that mediate allograft rejection (Kreisel et al., 2002b), and EC can be 
recognized by CD8
+
 T-cells through the indirect antigen presentation pathway involving 
cross-presentation of exogenous antigens (Valujskikh et al., 2002a; Bagai et al., 2005b; 
Limmer et al., 2000). These previous studies have depicted EC-CTL interaction as an almost 
exclusive encounter of two cell types. However, in a recent study, we have shown, using 
Tie2LacZ mice in combination with CD8
+
 T-cell TCR transgenics, that EC presenting a 
mhAg remain immunologically ignored by naïve CTL and that EC-associated mhAg has to be 
cross-presented by DC in order to elicit CD8
+
 T-cell activation (Bolinger et al., 2008). The 
results of the present study support the notion that DC represents a crucial intermediary cell in 
the interaction between EC and CTL. -gal peptide-pulsed DC that were adoptively 
transferred into recipients of Tie2-LacZ heart efficiently expanded EC-specific CTL. 
Importantly, prolonged antigen presentation by DC was mandatory for the development of TV 
in this experimental system.  
Infection with CMV is an important risk factor for TV in human transplant recipients 
(Valantine, 2004; Potena and Valantine, 2007), most likely through its ability to directly 
infect cells of the vascular wall (Wu et al., 1992). Furthermore, experimental studies have 
indicated that MCMV infection can exacerbate allograft rejection (Carlquist et al., 1993). The 
results from the present study are in line with this interpretation since antiviral T cell 
responses directed against the -gal antigen within the vasculature favoured the development 
of vascular inflammation. However, in the absence of concomitant strong alloimmune 
responses, MCMV-induced anti-EC CTL did not suffice to elicit the full pathology of chronic 
vascular rejection. It is likely that a significant acceleration of TV by CMV infection is based 
on a combination of various factors including (i) the particular vascular tropism of the virus 
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resulting in virus-induced T-cell responses against persisting viral antigens within the 
vasculature, and (ii) bystander cytokine-mediated augmentation of allo-T-cell responses. 
Likewise, atherosclerotic lesion formation in hypercholesterolemic mice can be accelerated 
through MCMV-induced bystander cytokines (Vliegen et al., 2004; Vliegen et al., 2005) and 
by the specific activation of T-cells reactive against viral antigens that persist in the 
vasculature (Krebs et al., 2007).  
Taken together, using a novel mouse model of CTL-mediated EC injury in heterotopic 
heart transplantation, we could demonstrate that activated CTL recognizing a mhAg 
specifically expressed on EC can elicit TV. Furthermore, this interaction is facilitated by DC 
as intermediary cells which promote prolonged antigen presentation within secondary 
lymphoid organs. Thus, therapeutic intervention should target DC-mediated T-cell activation, 
for example through blockade of critical costimulatory circuits to protect EC from CTL-
mediated injury following transplantation of vascularised organs. 
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6 Discussion 
Numerous factors contribute to the development of CTV. In addition to non-
immunological aspects, a number of cell-cell interactions play a key role in its initiation and 
maintenance. It is thus important to provide appropriate models with well-defined conditions 
for the dissection of the different features. 
6.1 Can EC activate naive CD8+ T-cells? 
The detailed interaction of EC with CD8
+
 T-cells has been investigated in several in vitro 
and in vivo studies. Most in vitro studies were based on allogeneic differences between EC 
and CD8
+
 T-cells (Kreisel et al., 2002a; Ma and Pober, 1998; Epperson and Pober, 1994; 
Bagai et al., 2005a; Pober et al., 1997). Only a few studies have assessed the role of EC 
presenting a mhAg to CD8
+
 T-cells (Marelli-Berg et al., 2000; Marelli-Berg et al., 2001). 
Many in vivo studies have been performed using combinations with allogeneic differences 
between host and donor (Kreisel et al., 2002a; Kreisel et al., 2002b; Valujskikh et al., 2002a) 
or have studied the role of specific EC populations, such as the liver sinusoidal EC (LSEC), 
which cross-present antigen (Berg et al., 2006; Limmer et al., 2000; Limmer et al., 2005). 
However, in these experimental settings cross-presentation by professional APC, the role of 
mhAg, or the direct interaction of EC with CD8
+
 T-cells could not be examined. 
Therefore, our transgenic mouse, with the expression of the well-defined model antigen  
β-gal in the vascular endothelium (Tie2-LacZ mice) combined with the use of TCR transgenic 
mice (Bg1mice) with CD8
+
 T-cells specific for a β-gal epitope, represents a suitable model for 
the investigation of the cognate interaction of vascular EC with CD8
+
  
T-cells. It is the first model that allows studying the mhAg-specific cell-cell interaction in 
vivo. Furthermore, by the generation of BM chimeric mice, facilitating the ablation of  
CD11c-positive BM-derived DC (CD11c-DTR mice), antigen presentation by other cells than 
EC could be considered and analyzed. 
In this work, we demonstrated that mhAg presentation by EC does neither lead to CD8
+
  
T-cell activation nor tolerization. This was shown by the fact that adoptively transferred  
β-gal-specific CD8+ T-cells ignored mhAg expressed on the vascular endothelium. However, 
antigen expressed on vascular EC was cross-presented by BM-derived DC and induced 
activation of adoptively transferred antigen-specific CD8
+
 T-cells.  
There are several explanations for the observed immunologic ignorance. First, it could be 
that levels of antigen expression in EC of Tie2-LacZ mice are too low. It has been shown that 
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low antigen dose lead to T-cell tolerance (Kurts et al., 1999). However, this is implausible in 
our study since there is sufficient EC-associated antigen present for enabling the indirect 
cross-presentation by BM-derived DC. Second, there is the possibility that EC possess an 
impaired capacity to present immunodominant peptides (Kummer et al., 2005) and therefore 
fail to interact with CD8
+
 T-cells. However, it seems more reasonable that it is the location 
and the availability of antigen which determine whether an immune response is induced 
(Zinkernagel et al., 1997). Antigen has to be presented in organized lymphoid tissue to induce 
an immune response since aly/aly mice, which lack secondary lymphoid organs, failed to 
reject vascularised organ transplants (Lakkis et al., 2000). In other words, antigens that never 
reach organized lymphoid tissue or only for a too short period of time or in too low quantities 
are not able to activate T-cells. Staying outside lymphoid tissue is even a trick used by some 
viruses, for example the papilloma virus that induces skin warts, to escape immune 
surveillance (Zinkernagel et al., 1997). A further example of antigen ignorance is a transgenic 
mouse model with LCMV glycoprotein (GP) expressed in islet cells of the pancreas under the 
rat insulin promoter (RIP). These mice do not spontaneously develop diabetes. However, 
rapidly after infection with LCMV that induces a potent CTL response, they become diabetic 
(Ohashi et al., 1991). Only after specific activation T-cells are able to migrate to the periphery 
where target cells present the antigen. This underscores the necessity of the antigen being 
transported and presented within secondary lymphoid organs. Unless antigen does not reach 
organised lymphoid tissue, potentially reactive T-cells may be present but become neither 
activated nor actively tolerized.  
In our study, EC present a mhAg and therefore provide “signal 1”, i.e., antigen, in the 
absence of “signal 2”, i.e., costimulation which should result in tolerization of the antigen-
specific CD8
+
 T-cells. It is reasonable to assume that cell-cell contact between EC and CD8
+
 
T-cells was not possible or not within the right environment to enable productive interaction 
between EC and naive CTL. Nevertheless, BM-derived DC cross-presented mhAg and thus 
induced CD8
+
 T-cell activation and proliferation, identifying DC as potent APC that present 
antigen to CD8
+
 T-cells within secondary lymphoid organs.  
We explain the controversial outcome as compared to previous studies investigating the 
capacity of EC to induce a CD8
+
 T-response by their in vitro settings, where cell-cell contact 
is guaranteed (Marelli-Berg et al., 2000; Marelli-Berg et al., 2001), but which do not 
correspond to the in vivo situation where cell-cell contact represents a major challenge. A 
further explanation is the use of allogeneic disparities between host and donor leading to a 
different starting-point with higher antigen amount and higher precursor frequency (Kreisel et 
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al., 2002a; Kreisel et al., 2002b; Valujskikh et al., 2002a). A further reason is the difference in 
antigen amount presented by EC. In the study performed by Limmer et al. antigen was 
supplied systemically to the liver. This huge amount of antigen was then cross-presented by 
LSEC and led to the tolerization of antigen-specific CD8
+
 T-cells (Limmer et al., 2000). It 
would be of major interest whether the threshold amount of antigen necessary for the 
induction of CD8
+
 T-cell tolerance, instead of ignorance as seen in a study by Kurts et al. 
(Kurts et al., 1999) could be achieved supplying Tie2-LacZ mice with such high amounts of 
antigen. To address this question, we are going to inject soluble β-gal antigen i.v. into  
Tie2-LacZ mice, thereafter TCR transgenic CD8
+
 T-cells are transferred and CD8
+
 T-cell 
activation analyzed. However, in the experimental settings by Limmer and Berg et al. (Berg et 
al., 2006; Limmer et al., 2000; Limmer et al., 2005) antigen cross-presentation by professional 
APC, as seen in our study, could not be excluded and therefore may be a further reason for the 
different outcome.  
In our study, steady-state BM-derived DC cross-presenting mhAg induced CD8
+
 T-cell 
activation. Although they present antigen in the absence of “danger” or any inflammatory 
reaction, they did not induce T-cell tolerization. However, it is possible that some of the 
transferred cells became activated during ex vivo preparation before adoptive transfer. But 
since proliferation in wild-type C57BL/6 mice was not observed, this possibility can be ruled 
out. A better explanation for the independence of costimulatory signals could be the precursor 
frequency of CD8
+
 T-cells. Precursor frequency has been shown to play a particular role that 
impacts T-cell proliferation, differentiation, and requirement for costimulation. Donor-
reactive T-cells primed at a low frequency exhibited an increased requirement for CD28- and 
CD40L-mediated costimulation, whereas donor-reactive T-cells primed above a certain 
threshold cannot become tolerized by the blockade of costimulatory pathways (Ford et al., 
2007) and thus overcome peripheral tolerance mechanisms. Furthermore, it has been 
demonstrated that vigorous allograft rejection occurs despite the absence of “danger” 
(Bingaman et al., 2000).  
However, in our model CD8
+ 
T-cells became indeed activated and proliferated but they did 
not acquire full effector functions. This phenomenon could be a result of the different 
requirements for a T-cell to proliferate and expand or to become a cytotoxic T-cell. 
(Hernandez et al., 2002; Valitutti et al., 1996). Taken together, our results indicate that cell-
cell contact between vascular EC and CD8
+
 T-cells did not occur or in an inadequate manner, 
whereas contact between DC and CD8
+
 T-cells was strong and long enough to trigger CD8
+
 
T-cell activation and proliferation. 
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Tie2-LacZ hearts and livers transplanted into C57BL/6 mice have been well accepted. The 
presentation of a mhAg did not lead to T-cell activation. Moreover, Tie2-LacZ hearts resided 
in the recipients for over 100 days without any signs of CTV. This is in contrast to the study 
of Hirozane et al. where presentation of mhAg (more than one) lead to the development of 
CTV until day 70 (Hirozane et al., 1995). In our study, transferred β-gal specific CD8+ T-cells 
have neither been activated nor tolerized by mhAg presentation via EC of the transplanted 
organs. mhAg on EC has been ignored. This confirms the results seen in Tie2-LacZ mice. 
Furthermore, the mhAg amount was too low to be cross-presented by BM-derived DC (Kurts 
et al., 1999).  
However, β-gal expression in Tie2-LacZ mice refers to a single mhAg only. In the study 
by Valujskikh et al. the male antigen H-Y represents more than one single mhAg and cross-
presentation of the H-Y antigens by host EC was enough to mediate skin graft rejection. This 
estimate could also be considered in our setting. Transplantation of male Tie2-LacZ hearts 
into female C57BL/6 recipients would augment mhAg number and amount. Thus, we could 
address the question whether increase in mhAg number influences CD8
+
 T-cell activation and 
whether EC can become target cells of specific CTL.  
Overall, CD8
+
 T-cell activation or CD8
+
 T-cell induced rejection of transplanted organs 
has only been observed in in vivo transplantation models with allogeneic differences between 
host and donor (Kreisel et al., 2002a; Kreisel et al., 2002b). This indicates that the high 
amount of antigen together with the high precursor frequency provides a stimulus strong 
enough to overcome the standard rules for T-cell priming and thus to activate CD8
+
 T-cells. 
In the case of a mhAg, we argue that these requirements are not fulfilled and CD8
+
 T-cells 
therefore ignore mhAg presented by vascular EC (Figure 16).  
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Figure 16: Minor histocompatibility antigen presented by vascular EC is ignored by naive CD8
+
 T-cells. CD8
+
 
T-cells do not become activated nor tolerized. 
 
6.2 Can EC become target cells of activated CTL? 
To find out whether antigen-specific CTL mediate injury to EC presenting a mhAg and 
whether these injuries are sufficient to induce TV, we heterotopically transplanted Tie2-LacZ 
hearts into C57BL/6 recipients. In order to activate β-gal specific CD8+ T-cells over a longer 
period of time, β-gal peptide-loaded, in vitro cultured DC were repetitively injected. Thus, a 
strong β-gal specific CD8+ T-cell response could still be measured on day 15 and the detailed 
interaction of EC with β-gal-specific CTL was assessed. Induction of a β-gal specific CTL 
response elicited severe vascular inflammation in transplanted Tie2-LacZ hearts. Furthermore, 
neointima formation and vascular occlusion could be observed leading thereby to the 
development of chronic vascular rejection. Infection with MCMV-LacZ was characterized by 
a less pronounced activation and a shorter time of β-gal-specific CTL responses and therefore 
led to reduced vascular inflammation in Tie2-LacZ hearts. 
These results suggest that once activated, β-gal specific CD8+ T-cells easily migrate to the 
periphery where they make cognate interactions with peptide/MHC complexes expressed on 
vascular EC, thereby engaging their effector machinery and leading to specific destruction of 
the EC. This indicates that the second antigen contact has less stringent costimulatory 
requirements. Furthermore, these findings identify EC presenting mhAg as target cells of 
specific activated CTL (Figure 17). Nevertheless, this issue is crucial in the context of GVHD 
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which is characterized by the presence of activated mhAg-specific CTL capable of EC 
destruction and thereby leading to CTV development (Mutis et al., 1999). Furthermore, EC 
injury has been shown to influence the outcome of CTV. 
However, we show that it is yet again the long-term antigen presentation and thus the long-
term CTL activation within secondary lymphoid organs which plays a key role in the 
induction of chronic vascular rejection. Short-time activation of CTL, as seen in MCMV-
LacZ infection, is clearly less efficient in inducing specific CTV. Despite the fact that 
MCMV-LacZ induces a strong specific and overall immune stimulation, we argue that it is the 
lack of chronic activation that leads to a less pronounced outcome of vascular inflammation, 
neointima thickening, and vessel occlusion. Additionally, this is even more evident when 
lesions of Tie2-LacZ hearts were compared with lesions in wild-type hearts. This 
phenomenon could be explained by the fact that MCMV preferentially infects and replicates 
in vascular EC (Jarvis and Nelson, 2002), together with the general immune stimulation it 
leads to cell infiltration and mild inflammation around the vessels in C57BL/6 mice. The use 
of TCR transgenic β-gal specific CD8+ T-cells in combination with MCMV-LacZ could be an 
approach to render the system more specific and enable the investigation of the influence of 
viral infections. This is of major interest since, as a consequence of immunosuppressive 
treatment in transplantation patients, viral reactivation may occur and accumulating evidence 
suggests that such virus reactivations resulting in chronic viral infection play a major role in 
the development of CTV. Beside herpes viruses, such as CMV, viral genomes including 
adenovirus have been found to correlate with the outcome of acute and chronic rejection 
(Potena et al., 2003). By the constant presence of antigen, chronic viral infections lead to the 
continuous stimulation of the immune system. The permanent release of pro-inflammatory 
cytokines favours local inflammation and allograft injury leading to CTV. Nonetheless, it has 
been shown that antiviral therapy in transplant patients leads to a prolonged graft life (Hodson 
et al., 2005; Potena et al., 2006). Furthermore, chronic immune reactivity against persisting 
antigen in the vasculature exacerbates atherosclerotic lesion formation (Krebs et al., 2007). 
However, there is evidence that the development of CTV is influenced by the simultaneous 
co-existence of a chronic viral infection. Therefore, MCMV-LacZ infection together with the 
transfer of β-gal-specific CD8+ and/or CD4+ T-cells will help to measure the influence of 
specific immune reactivity against a persisting antigen in the vasculature. Nevertheless, since 
MCMV-LacZ infection did not display a long-term activation of β-gal-specific CTL in our 
model, we are going to further use the β-gal recombinant and replication deficient adenovirus 
(Adeno-LacZ). After Adeno-LacZ infection a long-term β-gal-specific CTL response could be 
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observed. Infection of C57BL/6 mice with 2x10
9
 pfu Adeno-LacZ induces a β-gal-specific 
CTL response with its peak for the β-gal497-504 epitope on day 14 measured by MHC class I 
tetramer staining, whereas the CTL response for a second β-gal epitope, the β-gal96-103, 
increased over time and displayed more than 30% specific CD8
+
 T-cells on day 100 
identifying Adeno-LacZ as an ideal virus to test chronic immune stimulation in our 
transplantation model. 
Taken together our results corroborate studies performed with major histocompatibility 
disparities between donor and host, except that mhAg-specific CTL had to be generated by 
vaccination in our model. This is because of the lower antigen amount and particularly 
because of the lower precursor frequency of T-cells specific for a mhAg compared to 
alloreactive T-cells (Lindahl and Wilson, 1977; Suchin et al., 2001). Nonetheless, CTV has 
been proposed to represent a delayed-type hypersensitivity response against cells of the 
vascular wall (Libby et al., 1989; Mitchell and Libby, 2007). The present findings support this 
view by showing the link between direct T-cell-mediated EC injury and subsequent 
pathological remodelling of coronary arteries. However, since EC are target cells for activated 
CTL they clearly drive the process of chronic vascular rejection by their immune-mediated 
injuries (Valantine, 2003). Furthermore, EC persist in organ transplants and are thereby able 
to serve as a place for chronic inflammation, injuries, and subsequent chronic vascular 
rejection. 
However, one criticism that could be raised concerning our model is the use of a single 
mhAg which does not represent the “real” situation where donor and host differ in more than 
one mhAg and principally display major histocompatibility antigen differences. This lack 
could be bypassed, as already mentioned, by the transplantation of a male Tie2-LacZ heart 
into a female C57BL/6 recipient. Whether this simple change could lead to spontaneous T cell 
activation has to be investigated. Although it has already been shown that a male heart 
transplanted into female recipient did not lead to rejection (He et al., 2004a), the cumulating 
effect of a mhAg and the H-Y antigens has never been assessed. Moreover, the use of TCR 
transgenic β-gal specific CD8+ T-cells in combination with MCMV-LacZ infection could 
additionally augment the precursor frequency of specific CD8
+
 T-cells which has been shown 
to accelerate the pace and severity of vasculopathy (He et al., 2004a). Yet, it was the 
restriction to a single mhAg presented by EC that made it possible to independently study the 
effect of mhAg expression on EC and its role in the development of CTV. Furthermore, the 
lack of any immunosuppressive therapy, either by immunosuppressive drugs or via co-
stimulatory blockade, made it an ideal model for studying cell-cell interaction in chronic 
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vascular rejection. Indeed, we could clearly demonstrate that activated CTL recognizing a 
mhAg expressed on EC were able to induce TV. Furthermore, by showing the importance of 
DC as intermediary cells promoting prolonged antigen presentation within secondary 
lymphoid organs, we propose that therapeutic intervention should clearly target DC-mediated 
T-cell activation in order to prevent CTL-mediated injury of EC following transplantation. 
Still, our findings concerning MCMV-LacZ infection clearly show that virus clearance or 
injury healing are critical steps contributing to the development of CTV (Valantine, 2003). 
Taken together, chronic graft rejection is a complex disorder in which numerous known and 
unknown factors participate and it is in the end the overall sum of stimuli leading to the 
disease (Caforio et al., 2004; Goodman and Mohanakumar, 2003).  
In order to obtain more mechanistic insights, we plan to further investigate the role of IFNγ 
in the development of TV since it has been shown to have a number of actions on EC, such as 
up-regulation of MHC class I molecules. Transplantation of hearts from Tie2-LacZ mice 
lacking the IFNγ-receptor should display whether the release of IFNγ by T-lymphocytes 
accelerate TV development induced by β-gal-specific CTL through its effect on the activation 
status of EC.  
 
Figure 17: Activated CD8+ T-cells recognize minor histocompatibility antigen expressed on EC, thus EC 
become target cells of antigen-specific CTL. 
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6.3 CD4+ T-cell help 
It is known that both CD4
+
 and CD8
+
 T-cells contribute to allograft rejection. The central 
importance of CD4
+
 T-cells in the initiation of allograft rejection has been illustrated in 
multiple studies and there is no doubt that hematopoietic cells of donor and host origin, such 
as DC and macrophages, are potent activators of alloreactive CD4
+ 
T-cells. Furthermore, 
rejection of a solid organ mismatched for minor antigens is also dependent on CD4
+
 and 
CD8
+
 T-cells (Rosenberg and Singer, 1992; Filatenkov et al., 2005). Heart transplants with 
mhAg disparities are rapidly rejected, but only if they received both specific CD8
+
 and CD4
+
 
T-cells before transplantation (Filatenkov et al., 2005). Moreover, it has long been recognized 
that CD4
+
 T-cell help is essential for CD8
+
 T-cells, in particular for responses to some 
bacterial and viral infections (Bevan, 2004). However, it is the CD4
+
 T-cell help that renders 
the APC competent to efficiently stimulate naive CD8
+
 T-cells via CD40L-CD40 ligation 
(Ridge et al., 1998). Thus, the expression of B7 costimulatory molecules on DC (Yang and 
Wilson, 1996) is increased and the production of IL-12, which significantly augments CD8
+
 
T-cell responses, is stimulated (Filatenkov et al., 2005; Cella et al., 1996). This is of major 
importance since it is the DC that delivers the signals which decide whether there is T-cell 
immunity or tolerance (Steinman, 2003). CD4
+
 T-cells further assist CD8
+
 T-cells by 
providing IL-2. Moreover Hernandez et al. have shown that high numbers of in vitro activated 
specific CD4
+
 T-cells transferred into a transgenic mouse with antigen expressed in the 
pancreas could transform the tolerizing signal, resulting in CD8
+
 T-cell proliferation but not 
effector function, into a signal leading to the differentiation of CD8
+
 T-cells into effector cells 
(Hernandez et al., 2002). 
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Figure 18: Two models of help delivery to CTL. (a) The passive model: DC present antigen to T helper cells 
and CTL. Costimulatory signals are only provided to T helper cells. (b) The dynamic model: DC offer 
costimulation to both. They initially stimulate T helper cells, which, in turn, stimulates and “conditions” DC to 
differentiate to a state where they can directly costimulate CTL (Ridge et al., 1998). 
 
However, in our study the transfer of β-gal-specific CD8+ T-cells into Tie2-LacZ mice lead 
to activation and proliferation but not effector function of CD8
+
 T-cells, indicating that 
proliferative potential and the gain of effector function are independent events (Hernandez et 
al., 2002). It would be of major interest whether activated CD4
+
 T-cells could render DC 
competent to induce a potent CTL response in our mouse model. Therefore, we are going to 
investigate the influence of β-gal-specific CD4+ T-cells in this setting. Mice expressing a  
β-gal-specific TCR on CD4+ T-cells (Bg2 mice) have been kindly provided by Dr. Nicolas 
Restifo. The properties of this novel TCR transgenics are currently investigated. Once the 
basic characteristics of the Bg2 TCR have been recorded, it will be investigated whether 
adoptively transferred TCR transgenic CD4
+
 T-cells are activated by presenting DC in vivo. If 
yes, are they able to transform the CD8
+
 T-cell response in order that CD8
+
 T-cells reach 
effector function? If no, is there nevertheless a change in the CD8
+
 T-cell response due to the 
Discussion 
- 88 - 
 
release of cytokines such as IL-2? To address this question preactivated β-gal-specific CD4+ 
T-cells (Bg2) together with CD8
+
 T-cells will be transferred into Tie2-LacZ mice and CD8
+
 
T-cell response will be assessed. A positive outcome of CD4
+
 T-cell help would have 
significant consequences in transplantations where both CD4
+
 and CD8
+
 T-cells become 
activated. This would lead to specific CTL activation, the induction of EC injury, and 
subsequently to the development of CTV.  
However, the transfer of CD4
+
 T-cells could also be of major interest after the 
transplantation of a Tie2-LacZ heart into a C57BL/6 recipient. Naive and preactivated CD4
+
 
T-cells together with CD8
+
 T-cells could be adoptively transferred into transplanted mice and 
the development of CTV could be analyzed. The combined injection with DC is not necessary 
since DC cultivated ex vivo are fully activated and therefore able to induce a CTL response, as 
well as the injection of MCMV-LacZ which leads to fully activated CTL.  
Nevertheless, knowing that EC cannot directly activate CD8
+
 T-cells, the requirements that 
render a DC a fully activated and competent APC are worth to be assessed. Therefore, the 
investigation of CD4
+
 T-cell help in the process of chronic vascular rejection will further 
explain the detailed cell-cell interaction during the development of TV and thus reveal new 
strategies for the prevention of late graft rejection. 
6.4 CD4+CD25+Foxp3+ regulatory T-cells 
Isolated and activated vascular EC have been shown to stimulate allogeneic 
CD4
+
CD25
+
Foxp3
+
 Treg cells, although they are known to be unable to induce cell division 
in allogeneic CD4
+
 T-cells. Treg cells clearly inhibited allogeneic T-cell proliferation in vitro 
and in vivo (Kreisel et al., 2004; Krupnick et al., 2005). However, the in vivo induction of 
CD4
+
CD25
+
Foxp3
+
 Treg cells has not been shown and therefore the contribution of 
hematopoietic APC in the induction of Treg cells could not be excluded. This aspect must be 
considered since it has been demonstrated that Treg cells become activated via the interaction 
of antigen presenting DC in secondary lymphoid organs (Sakaguchi, 2004). Moreover, spleen 
has clearly been shown to play an imperative role in the maintaining of tolerance towards 
heart allografts induced by CD4
+
CD25
+
Foxp3
+
 Treg cells (Chosa et al., 2007) confirming the 
significance of secondary lymphoid organs for T-cell priming. To dissect the role of 
professional APC versus non-hematopoietic APC, such as EC, in the induction of 
CD4
+
CD25
+
Foxp3
+
 Treg cells further in vivo studies are necessary. We are going to assess 
Treg cell stimulation in Tie2-LacZ mice where mhAg expression is confined to the vascular 
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endothelium by FACS analysis. In order to exclude antigen presentation by BM-derived cells, 
BM-chimeric mice could be generated and the induction of Treg cells analyzed.  
CD4
+
CD25
+
Foxp3
+
 Treg cells have further been demonstrated to regulate alloreactive  
T-cell responses and the acute rejection of single class II MHC-disparate heart allografts 
(Schenk et al., 2005). Moreover, in a very recent study the use of ex vivo expanded 
CD4
+
CD25
+
Foxp3
+
 T regulatory cells has been suggested as therapeutics in combination with 
irradiation to treat and prevent GVHD in BM transplantation (Joffre et al., 2008). However, 
only after knowing the exact mechanisms of how Treg cells become activated, in particular 
after organ transplantation, new strategies using Treg cells to induce specific tolerance 
towards the graft transplant can be established. Therefore, the detailed role of Treg cells in 
solid graft transplantation and the comprehension of the active suppressive mechanisms which 
induce long-term tolerance may help to generate new therapies and has thus to be further 
assessed. 
In several rodent transplantation studies, it has been shown that alloantigen-specific and 
suppressive CD4
+
CD25
+
 Treg cells accumulated within the graft and controlled effector cells 
by their regulatory mechanism (Cobbold et al., 2004; Graca et al., 2002). Therefore we 
suggest that there must be an interaction between Treg cells, effector cells and APC leading to 
tolerance induction. To assess the detailed role of Treg cells in transplantation, transgenic 
DEREG mice will be used (Lahl et al., 2007). DEREG mice express a diphtheria toxin 
receptor (DTR)-enhanced GFP fusion protein under the control of the foxp3 locus which 
allows both the detection of Foxp3
+
 regulatory T cells and their inducible depletion via DT 
injection. Therefore we are going to transplant Tie2-LacZ hearts into DEREG recipients. In a 
first set of experiments the induction of CD4
+
CD25
+
Foxp3
+
 Treg cells will be studied by 
FACS analysis and immune histochemistry of heart slides. To find out whether 
CD4
+
CD25
+
Foxp3
+
 regulatory T cells participate in tolerance towards Tie2-LacZ hearts in 
C57BL/6 recipients we are going to deplete Treg cells by the injection of DT. Depending on 
the outcome, the interaction between Treg cells and DC as well as effector T cells will be 
further analyzed. With the help of transgenic mice, facilitating the depletion of CD11c
+
 DC, 
and via the transfer of β-gal-specific CD4+ T-cells further insights into the detailed interplay 
between those cells will be achieved. We will additionally investigate the role of IFNγ via the 
transplantation of Tie2-LacZ hearts lacking the IFNγ-receptor since it has been demonstrated 
that IFNγ plays a key role in allograft tolerance based on Treg cells (Thebault et al., 2007). 
However, the options given by the well established transplantation model and the numerous 
available transgenic mice are almost without limits. Nevertheless, a further step is the 
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establishment of solid organ transplantation leading to physiologically functional organs. In 
order to fulfil this requirement we are going to orthotopically transplant kidney grafts. 
Chronic rejection is the most prevalent reason of renal transplant failure as well. In most cases 
the histopathology is not specific, such as fibrointima thickening of arteries, interstitial 
fibrosis, and tubular atrophy, but characterized by glomerulopathy and multilayering of the 
peritubular capillaries. However, a main advantage of renal transplantations is the easiness of 
measuring the loss of function by controlling the creatinine clearance and certainly the 
proximity to the conditions in humans since a host kidney is replaced by a donor kidney that 
takes over its physiological role. 
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7.3 Abbreviations 
β-gal  β-galactosidase 
Ab   Antibody 
Ag   Antigen 
AIRE  Human autoimmune regulator protein 
APC  Allophycocyanin 
APC  Antigen-presenting cell 
B6   C57BL/6 
BM   Bone marrow 
BSS  Balanced salt solution 
CCR  Chemokine receptor, C-C subgroup 
CD   Cluster of differentiation 
CD40L  CD40 ligand 
CD62L  CD62 L-Selectin 
cDNA  Cloned deoxyribonucleic acid 
CFSE  Carboxyfluoroscein diacetatsuccinimidyl ester 
CMV  Cytomegalovirus 
CTL  Cytotoxic T-lymphocyte 
CTLA4  Cytotoxic T-lymphocyte antigen 4 
CTLA4-lg  Cytotoxic T-lymphocyte antigen 4-ligand 
CTV  Chronic transplant vasculopathy 
DC   Dendritic cell 
DEPC  Diethylene pyrocarbonate 
DEREG  Depletion of regulatory T-cells 
DMEM  Dulbecco’s modified Eagle’s medium 
DNA  Deoxyribonucleic acid 
DT   Diphteria toxin 
DTR  Diphteria toxin receptor 
EC   Endothelial cell 
EL-4  Mouse thymome cell line 
EVG  Elastic van Giesson 
FACS  Fluorescence activated cell scanning/sorting 
FBS  Fetal bovine serum 
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FCS  Fetal calf serum 
FITC  Fluorescein isothiocyanat 
Foxp3  Forkhead box protein 3 
GFP  Green fluorescent protein 
GM-CSF  Granulocyte/macrophage colony-stimulating factor 
GP   Glycoprotein 
GVHD  Graft versus host disease 
HBSS  Hanks balanced salt solution 
HCS  Hematopoietic stem cell 
HCMV  Human cytomegalovirus 
HLA  Human leukocyte antigen 
i.p.   Intraperitoneal 
i.v.   Intravenous 
ICAM  Intercellular adhesion molecule 
IFN   Interferon 
Ig   Immunglobulin 
IL   Interleukin 
IMDM  Iscove’s modified Dulbecco’s medium 
IP-10   Interferon-inducible protein 10 
kDa   Kilodalton 
LacZ  Gene encoding for the β-galactosidase protein 
LCMV  Lymphocyte choriomeningitis virus 
LFA  Lymphocyte-function-associated antigen 1 
LN   Lymph node 
LPS  Lipopolysaccharide 
LSEC  Liver sinusoidal endothelial cell 
LT   Lymphotoxin 
mAb   Monoclonal antibody 
MAC-1  Membrane-attack complex 
MACS  Magnetic assisted cell sorting 
MCMV  Murine cytomegalovirus 
MCP-1  Monocyte chemoattractant protein 1 
MEM  Minimal essential medium 
mhAg  Minor histocompatibility antigen 
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MHC  Major histocompatibility complex 
MIG  Monokine induced by interferon gamma 
MIP-1α  Macrophage inflammatory protein 
MLN  Mesenteric lymphe node 
mTECs  Medullary thymic epithelial cells 
NP   Nucleoprotein 
PBL  Peripheral blood lymphocytes 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PD-1  Programmed death-1 
PD-L  Programmed death-ligand 
PDGF  Platelet-derived growth factor 
PE   Phycoerithrin 
PerCp  Peridinin Chlorophyll protein 
pfu   Plaque forming unit 
PMA  Phorbol myristate acetate 
RANTES  Regulated on activation, normal T expressed and secreted 
RCMV  Rat cytomegalovirus 
RIP   Rat insulin promoter 
RNA  Ribonucleic acid 
RT-PCR  Reverse transcriptase polymerase chain reaction 
SEM  Standard error of the mean 
s.c.   Subcutanous 
SM   Smooth muscle 
SMC  Smooth muscle cell 
T2   Tie2-LacZ 
TBP  TATA binding protein 
TCR  T-cell receptor 
TGF-β  Transforming growth factor beta 
Th   T helper cell 
TLR  Toll-like receptor 
TNF  Tumor necrosis factor 
TNFR  Tumor necrosis factor receptor 
Treg  T regulatory cell 
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TSAs  Tissue-specific antigens 
TV   Transplant vasculopathy 
Wt   Wild type 
VEGF  Vascular endothelial growth factor 
VLA-4  Very late antigen 4 
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schwierigsten Zeiten am meisten Unterstützung und Erholung geboten. Weiter hat er sich die 
Riesenmühe gemacht, meine Arbeit zu lesen. Vielen lieben Dank! 
Und zuletzt möchte ich auch meinen Eltern und Geschwistern ganz herzlich für ihre 
Unterstützung danken. Nur mit ihrer Hilfe war es möglich, dass ich all meine Ziele erreichen 
konnte.  
 
 
  
  Appendix  
 
- 115 - 
 
7.5 Bibliography 
Krebs, P., E. Scandella, B. Bolinger, S. Miller, and B. Ludewig. 2007. Chronic immune 
reactivity against persisting microbial antigen in the vasculature exacerbates atherosclerotic 
lesion formation. Arteriosclerosis, Thrombosis & Vascular Biol. 27:2206-13. 
 
Bolinger, B., P. Krebs, Y. Tian, D. Engeler, E. Scandella, S. Miller, D.C. Palmer, N.P. 
Restifo, P.-A. Clavien and B. Ludewig. 2008. Immunologic ignorance of vascular endothelial 
cells expressing minor histocompatibility antigen. Blood 2008 May 1; 111 (9): 4588-95.  
 
Scandella, E., B. Bolinger, E. Lattmann, S. Miller, S. Favre, D.R. Littman, D. Finke, S. 
Luther, T.M. Junt, and B. Ludewig. 2008. Restoration of lymphoid organ integrity through 
interaction of lymphoid tissue inducer cells with stromal cells. Nature Immunology 2008 Jun; 
9 (6): 667-75. 
 
Lang, P.A., C. Contaldo, P. Georgiev, A.M. El-Badry, M. Recher, M. Kurrer, L. Cervantes-
Barragan, B. Bolinger, B. Ludewig, D. Merkler, B. Odermatt, M. Bader, R. Graf, P.-A. 
Clavien, H. Hengartner, R.M. Zinkernagel, and K.S. Lang. Protraction of viral hepatitis by 
platelet-derived serotonin. Nature Medicine 2008 Jul; 14 (7): 756-761. 
 
Kang, T., G. Oh, E. Scandella, B. Bolinger, B. Ludewig, A. Kovalenko, and D. Wallach. Cell 
death induction yet not non-apoptotic functions of caspase-8 is compromised in BAC 
transgenic mice with mutation of its initial self-processing site. Journal of Immunology 2008 
Aug 15; 181 (4): 2522-32. 
 
Daniel Engeler
*
, Beatrice Bolinger
*
,
 
Philippe Krebs, Simone Miller, Matthias Hoffmann, 
Pierre-Alain Clavien, Yinghua Tian, and Burkhard Ludewig. Dendritic cell-activated, 
endothelial cell-specific CTL recognizing a minor histocompatibility antigen rapidly induce 
transplant vasculopathy (submitted). 
* First shared 
 
Zinkernagel, M., P.Krebs, S.Miller, B.Bolinger, and B.Ludewig. Immunopathologic basis of 
lymphocytic choriomeningitis virus-induced chorioretinitis. Journal of Virology 2008 Oct 22 
[E pub ahead of print]. 
  
Appendix 
- 116 - 
 
7.6 Curriculum Vitae 
 
Name   Beatrice Barbara Bolinger 
Date of Birth  April 24, 1977 
Nationality  Swiss 
 
 
Education 
 
2004-2008 PhD thesis in the group of PD Dr. B. Ludewig, Labor-
forschungsabteilung, Kantonsspital St.Gallen 
 “Interaction of vascular endothelial cells with CD8+ T-cells in vivo” 
2002 Diploma thesis in the group of Prof. Dr. W. Schaffner at the Institute of 
Pathology, University of Basel 
 “Induction of apoptosis by phytoestrogenes and plant extracts on 
tumour cells: An in-vitro study on human cell cultures” 
1997-2002 Studies in Pharmacy, University of Basel 
1993-1996 Gymnasium Muttenz, Type C (mathematics) 
 
 
 
Work experience 
 
2002-2004 Pharmacist at Adler Apotheke, Liestal 
2000-2002 Part time substitution as assistant pharmacist at Kirschgartenapotheke, 
Basel 
2000 Practical training at the pharamacy of Hôpital Riviera, Site du 
Samaritain, Vevey 
1999-2000 Practical training at Pharmacie de Chailly, Lausanne 
 
 
 
Languages 
  
German Mother tongue 
English Fluent, written and oral 
French Fluent, written and oral 
Spanish Basic knowledge 
Italian Basic knowledge 
